ZA200506527B - Amino acid phenoxy ethers - Google Patents
Amino acid phenoxy ethers Download PDFInfo
- Publication number
- ZA200506527B ZA200506527B ZA200506527A ZA200506527A ZA200506527B ZA 200506527 B ZA200506527 B ZA 200506527B ZA 200506527 A ZA200506527 A ZA 200506527A ZA 200506527 A ZA200506527 A ZA 200506527A ZA 200506527 B ZA200506527 B ZA 200506527B
- Authority
- ZA
- South Africa
- Prior art keywords
- amino
- salts
- dione
- phenoxy
- carboxyethyl
- Prior art date
Links
- -1 Amino acid phenoxy ethers Chemical class 0.000 title claims description 50
- 150000003839 salts Chemical class 0.000 claims description 342
- 150000001875 compounds Chemical class 0.000 claims description 138
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 96
- COWNFYYYZFRNOY-UHFFFAOYSA-N oxazolidinedione Chemical compound O=C1COC(=O)N1 COWNFYYYZFRNOY-UHFFFAOYSA-N 0.000 claims description 44
- 229910052739 hydrogen Inorganic materials 0.000 claims description 40
- 125000000217 alkyl group Chemical group 0.000 claims description 31
- 239000001257 hydrogen Substances 0.000 claims description 28
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 24
- 229910052717 sulfur Inorganic materials 0.000 claims description 24
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 23
- 239000011593 sulfur Substances 0.000 claims description 23
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- 239000001301 oxygen Substances 0.000 claims description 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 20
- 206010061218 Inflammation Diseases 0.000 claims description 19
- 208000008589 Obesity Diseases 0.000 claims description 19
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 230000004054 inflammatory process Effects 0.000 claims description 19
- 235000020824 obesity Nutrition 0.000 claims description 19
- 102000004127 Cytokines Human genes 0.000 claims description 16
- 108090000695 Cytokines Proteins 0.000 claims description 16
- 235000001014 amino acid Nutrition 0.000 claims description 16
- 229940024606 amino acid Drugs 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 102000004877 Insulin Human genes 0.000 claims description 13
- 108090001061 Insulin Proteins 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 229940125396 insulin Drugs 0.000 claims description 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 239000008103 glucose Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 201000006417 multiple sclerosis Diseases 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 208000026278 immune system disease Diseases 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 206010022489 Insulin Resistance Diseases 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 235000009582 asparagine Nutrition 0.000 claims description 3
- 229960001230 asparagine Drugs 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 235000021588 free fatty acids Nutrition 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- TWWVONQNEVLIIH-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenoxy]phenyl]propanoate Chemical compound C1=CC(CC(N)C(=O)OC)=CC=C1OC(C=C1)=CC=C1C=C1C(=O)NC(=O)S1 TWWVONQNEVLIIH-UHFFFAOYSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- IEAGYIIYKUNMJQ-UHFFFAOYSA-N 2-amino-3-[2-amino-4-[4-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]phenoxy]phenyl]propanoic acid Chemical compound C1=C(N)C(CC(N)C(O)=O)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)O1 IEAGYIIYKUNMJQ-UHFFFAOYSA-N 0.000 claims description 2
- LWDJANBWPHCGCW-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid Chemical compound C1=CC(CC(N)C(O)=O)=CC=C1OC(C(=C1)C(F)(F)F)=CC=C1CC1C(=O)NC(=O)S1 LWDJANBWPHCGCW-UHFFFAOYSA-N 0.000 claims description 2
- WEEOLUNAKUDMST-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methylphenoxy]phenyl]propanoic acid Chemical compound C=1C=C(OC=2C=CC(CC(N)C(O)=O)=CC=2)C(C)=CC=1CC1SC(=O)NC1=O WEEOLUNAKUDMST-UHFFFAOYSA-N 0.000 claims description 2
- OVLHQLDCDXHBEV-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-nitrophenoxy]phenyl]propanoic acid Chemical compound C1=CC(CC(N)C(O)=O)=CC=C1OC(C(=C1)[N+]([O-])=O)=CC=C1CC1C(=O)NC(=O)S1 OVLHQLDCDXHBEV-UHFFFAOYSA-N 0.000 claims description 2
- TYXMZIRHGYCJLF-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]-2-fluorophenyl]propanoic acid Chemical compound C1=C(F)C(CC(N)C(O)=O)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 TYXMZIRHGYCJLF-UHFFFAOYSA-N 0.000 claims description 2
- TYOBQYNMHUFIET-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]-2-nitrophenyl]propanoic acid Chemical compound C1=C([N+]([O-])=O)C(CC(N)C(O)=O)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 TYOBQYNMHUFIET-UHFFFAOYSA-N 0.000 claims description 2
- BYCDADIRSHRLAO-UHFFFAOYSA-N 3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]phenyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound C1=CC(CC(NC(=O)OC(C)(C)C)C(O)=O)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 BYCDADIRSHRLAO-UHFFFAOYSA-N 0.000 claims description 2
- 108090001069 Chymopapain Proteins 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 150000001483 arginine derivatives Chemical class 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- HYQIZYXZQSYDCJ-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]phenoxy]-3,5-difluorophenyl]propanoate Chemical compound FC1=CC(CC(N)C(=O)OC)=CC(F)=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)O1 HYQIZYXZQSYDCJ-UHFFFAOYSA-N 0.000 claims description 2
- MPFQVGALPSRHIA-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]phenoxy]-3-(trifluoromethyl)phenyl]propanoate Chemical compound FC(F)(F)C1=CC(CC(N)C(=O)OC)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)O1 MPFQVGALPSRHIA-UHFFFAOYSA-N 0.000 claims description 2
- LQOFRSDZPNFATG-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-nitrophenoxy]phenyl]propanoate Chemical compound C1=CC(CC(N)C(=O)OC)=CC=C1OC(C(=C1)[N+]([O-])=O)=CC=C1CC1C(=O)NC(=O)S1 LQOFRSDZPNFATG-UHFFFAOYSA-N 0.000 claims description 2
- ILGUXHBABDWGAU-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]-2,3-difluorophenyl]propanoate Chemical compound FC1=C(F)C(CC(N)C(=O)OC)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 ILGUXHBABDWGAU-UHFFFAOYSA-N 0.000 claims description 2
- OGXRFCWCSMPYKS-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]phenyl]propanoate Chemical compound C1=CC(CC(N)C(=O)OC)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 OGXRFCWCSMPYKS-UHFFFAOYSA-N 0.000 claims description 2
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 claims description 2
- 230000000269 nucleophilic effect Effects 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 6
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims 5
- DIQYSJCKUNKKIG-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid Chemical compound C1=CC(CC(N)C(O)=O)=CC=C1OC(C(=C1)C(F)(F)F)=CC=C1CC1C(=O)NC(=O)O1 DIQYSJCKUNKKIG-UHFFFAOYSA-N 0.000 claims 1
- VQTYLKRLKRBOSC-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]-3-(trifluoromethyl)phenoxy]phenyl]propanoic acid Chemical compound C1=CC(CC(N)C(O)=O)=CC=C1OC(C=C1C(F)(F)F)=CC=C1CC1C(=O)NC(=O)O1 VQTYLKRLKRBOSC-UHFFFAOYSA-N 0.000 claims 1
- COKASQDIFJTIPJ-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]-3-fluorophenoxy]phenyl]propanoic acid Chemical compound C1=CC(CC(N)C(O)=O)=CC=C1OC(C=C1F)=CC=C1CC1C(=O)NC(=O)O1 COKASQDIFJTIPJ-UHFFFAOYSA-N 0.000 claims 1
- XPPLRZCCIPXNDA-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]phenoxy]-3,5-difluorophenyl]propanoic acid Chemical compound FC1=CC(CC(N)C(O)=O)=CC(F)=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)O1 XPPLRZCCIPXNDA-UHFFFAOYSA-N 0.000 claims 1
- UMVUKMXAGFOOJS-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]phenoxy]-3-(trifluoromethyl)phenyl]propanoic acid Chemical compound FC(F)(F)C1=CC(CC(N)C(O)=O)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)O1 UMVUKMXAGFOOJS-UHFFFAOYSA-N 0.000 claims 1
- BUSVRBBBHSSHOL-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-3,5-difluorophenoxy]phenyl]propanoic acid Chemical compound C1=CC(CC(N)C(O)=O)=CC=C1OC(C=C1F)=CC(F)=C1CC1C(=O)NC(=O)S1 BUSVRBBBHSSHOL-UHFFFAOYSA-N 0.000 claims 1
- YNEPUGHHHFPVLW-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-3-(trifluoromethyl)phenoxy]phenyl]propanoic acid Chemical compound C1=CC(CC(N)C(O)=O)=CC=C1OC(C=C1C(F)(F)F)=CC=C1CC1C(=O)NC(=O)S1 YNEPUGHHHFPVLW-UHFFFAOYSA-N 0.000 claims 1
- HEQHAWYLDXOVNM-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]-2-(trifluoromethyl)phenyl]propanoic acid Chemical compound C1=C(C(F)(F)F)C(CC(N)C(O)=O)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HEQHAWYLDXOVNM-UHFFFAOYSA-N 0.000 claims 1
- XXAXVMUWHZHZMJ-UHFFFAOYSA-N Chymopapain Chemical compound OC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O XXAXVMUWHZHZMJ-UHFFFAOYSA-N 0.000 claims 1
- 241000458243 Viana Species 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 235000001727 glucose Nutrition 0.000 claims 1
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- WCOQWNANGBUHBJ-UHFFFAOYSA-N methyl 2-amino-3-[2-amino-4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]phenyl]propanoate Chemical compound C1=C(N)C(CC(N)C(=O)OC)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 WCOQWNANGBUHBJ-UHFFFAOYSA-N 0.000 claims 1
- UVSDJMFVQROZFT-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-(1,3-thiazolidin-5-ylmethyl)phenoxy]-2-(trifluoromethyl)phenyl]propanoate Chemical compound C1=C(C(F)(F)F)C(CC(N)C(=O)OC)=CC=C1OC(C=C1)=CC=C1CC1SCNC1 UVSDJMFVQROZFT-UHFFFAOYSA-N 0.000 claims 1
- LQTXFKOPAKSRPR-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]-2,3-difluorophenoxy]phenyl]propanoate Chemical compound C1=CC(CC(N)C(=O)OC)=CC=C1OC(C(=C1F)F)=CC=C1CC1C(=O)NC(=O)O1 LQTXFKOPAKSRPR-UHFFFAOYSA-N 0.000 claims 1
- MNGYHHXEAHLKIC-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]-2-(trifluoromethyl)phenoxy]phenyl]propanoate Chemical compound C1=CC(CC(N)C(=O)OC)=CC=C1OC(C(=C1)C(F)(F)F)=CC=C1CC1C(=O)NC(=O)O1 MNGYHHXEAHLKIC-UHFFFAOYSA-N 0.000 claims 1
- LNXIYYYEFBIJMP-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-3,5-difluorophenoxy]phenyl]propanoate Chemical compound C1=CC(CC(N)C(=O)OC)=CC=C1OC(C=C1F)=CC(F)=C1CC1C(=O)NC(=O)S1 LNXIYYYEFBIJMP-UHFFFAOYSA-N 0.000 claims 1
- GUPWMRKXFIBJSD-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-3-(trifluoromethyl)phenoxy]phenyl]propanoate Chemical compound C1=CC(CC(N)C(=O)OC)=CC=C1OC(C=C1C(F)(F)F)=CC=C1CC1C(=O)NC(=O)S1 GUPWMRKXFIBJSD-UHFFFAOYSA-N 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 125000002876 tyrosin-O(4)-yl group Chemical group [H]OC(=O)C(N([H])[H])C([H])([H])C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 150000003667 tyrosine derivatives Chemical class 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 25
- 239000002904 solvent Substances 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 15
- 206010012601 diabetes mellitus Diseases 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 229940125782 compound 2 Drugs 0.000 description 10
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 10
- 235000019786 weight gain Nutrition 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 108700012920 TNF Proteins 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 208000027866 inflammatory disease Diseases 0.000 description 7
- 229960004586 rosiglitazone Drugs 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 208000030159 metabolic disease Diseases 0.000 description 6
- 230000004584 weight gain Effects 0.000 description 6
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 5
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 239000001632 sodium acetate Substances 0.000 description 5
- 235000017281 sodium acetate Nutrition 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 108010092277 Leptin Proteins 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 229940100389 Sulfonylurea Drugs 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000011759 adipose tissue development Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 230000003345 hyperglycaemic effect Effects 0.000 description 3
- 239000011261 inert gas Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical class C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102100039065 Interleukin-1 beta Human genes 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000001994 activation Methods 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 230000002293 adipogenic effect Effects 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 2
- 150000008046 alkali metal hydrides Chemical class 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000009229 glucose formation Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- YDJMOIJPBNTUAU-UHFFFAOYSA-N methyl 3-[2-(4-formylphenoxy)phenyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)NC(C(=O)OC)CC1=CC=CC=C1OC1=CC=C(C=O)C=C1 YDJMOIJPBNTUAU-UHFFFAOYSA-N 0.000 description 2
- SARPBCXOAPTYNU-UHFFFAOYSA-N methyl 3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenoxy]phenyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound C1=CC(CC(C(=O)OC)NC(=O)OC(C)(C)C)=CC=C1OC(C=C1)=CC=C1C=C1C(=O)NC(=O)S1 SARPBCXOAPTYNU-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- 125000006536 (C1-C2)alkoxy group Chemical group 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- XUBIOWXXEXLHEO-UHFFFAOYSA-N 2-amino-3-[2-amino-4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]phenyl]propanoic acid Chemical compound C1=C(N)C(CC(N)C(O)=O)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 XUBIOWXXEXLHEO-UHFFFAOYSA-N 0.000 description 1
- LVSLBYSKKZGLOY-UHFFFAOYSA-N 2-amino-3-[4-[2-amino-4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]phenyl]propanoic acid Chemical compound C1=CC(CC(N)C(O)=O)=CC=C1OC(C(=C1)N)=CC=C1CC1C(=O)NC(=O)S1 LVSLBYSKKZGLOY-UHFFFAOYSA-N 0.000 description 1
- LMVXXXFHMCNCKW-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]-2-fluorophenoxy]phenyl]propanoic acid Chemical compound C1=CC(CC(N)C(O)=O)=CC=C1OC(C(=C1)F)=CC=C1CC1C(=O)NC(=O)O1 LMVXXXFHMCNCKW-UHFFFAOYSA-N 0.000 description 1
- VLMFSKUOKJCFDN-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]-2-nitrophenoxy]phenyl]propanoic acid Chemical compound C1=CC(CC(N)C(O)=O)=CC=C1OC(C(=C1)[N+]([O-])=O)=CC=C1CC1C(=O)NC(=O)O1 VLMFSKUOKJCFDN-UHFFFAOYSA-N 0.000 description 1
- YQTJDLBNHWNLGS-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]phenoxy]-2-methylphenyl]propanoic acid Chemical compound C1=C(CC(N)C(O)=O)C(C)=CC(OC=2C=CC(CC3C(NC(=O)O3)=O)=CC=2)=C1 YQTJDLBNHWNLGS-UHFFFAOYSA-N 0.000 description 1
- BDENRQFNAYEAPJ-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]phenoxy]-3-fluorophenyl]propanoic acid Chemical compound FC1=CC(CC(N)C(O)=O)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)O1 BDENRQFNAYEAPJ-UHFFFAOYSA-N 0.000 description 1
- GYWZNBVJXWDKRK-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]phenoxy]phenyl]propanoic acid Chemical compound C1=CC(CC(N)C(O)=O)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)O1 GYWZNBVJXWDKRK-UHFFFAOYSA-N 0.000 description 1
- CJROKHCWPDOALK-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2,3-difluorophenoxy]phenyl]propanoic acid Chemical compound C1=CC(CC(N)C(O)=O)=CC=C1OC(C(=C1F)F)=CC=C1CC1C(=O)NC(=O)S1 CJROKHCWPDOALK-UHFFFAOYSA-N 0.000 description 1
- OHLRDQJOXBRKKB-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-fluorophenoxy]phenyl]propanoic acid Chemical compound C1=CC(CC(N)C(O)=O)=CC=C1OC(C(=C1)F)=CC=C1CC1C(=O)NC(=O)S1 OHLRDQJOXBRKKB-UHFFFAOYSA-N 0.000 description 1
- ZZJZSWZKWVLMFH-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]-3-(trifluoromethyl)phenyl]propanoic acid Chemical compound FC(F)(F)C1=CC(CC(N)C(O)=O)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 ZZJZSWZKWVLMFH-UHFFFAOYSA-N 0.000 description 1
- JZPIQKXXYDDYBU-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]-3-fluorophenyl]propanoic acid Chemical compound FC1=CC(CC(N)C(O)=O)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 JZPIQKXXYDDYBU-UHFFFAOYSA-N 0.000 description 1
- LPBFRHDVZVXTSO-UHFFFAOYSA-N 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]phenyl]propanoic acid Chemical compound C1=CC(CC(N)C(O)=O)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 LPBFRHDVZVXTSO-UHFFFAOYSA-N 0.000 description 1
- IPUDBCXGMBSQGH-UHFFFAOYSA-N 2-methoxybutan-1-ol Chemical compound CCC(CO)OC IPUDBCXGMBSQGH-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical class OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 101100167365 Caenorhabditis elegans cha-1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101001013648 Homo sapiens Methionine synthase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 206010022491 Insulin resistant diabetes Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical group NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102100031775 Leptin receptor Human genes 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Chemical group NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Chemical group OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229940126033 PPAR agonist Drugs 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 238000011803 SJL/J (JAX™ mice strain) Methods 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Chemical group 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000002660 insulin-secreting cell Anatomy 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 230000004322 lipid homeostasis Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- MJGFBOZCAJSGQW-UHFFFAOYSA-N mercury sodium Chemical compound [Na].[Hg] MJGFBOZCAJSGQW-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- VSEVDYVECLOBAX-UHFFFAOYSA-N methyl 2-amino-3-[4-[2-amino-4-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]phenoxy]phenyl]propanoate Chemical compound C1=CC(CC(N)C(=O)OC)=CC=C1OC(C(=C1)N)=CC=C1CC1C(=O)NC(=O)O1 VSEVDYVECLOBAX-UHFFFAOYSA-N 0.000 description 1
- DTTSMAZTBFTAII-UHFFFAOYSA-N methyl 2-amino-3-[4-[2-amino-4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]phenyl]propanoate Chemical compound C1=CC(CC(N)C(=O)OC)=CC=C1OC(C(=C1)N)=CC=C1CC1C(=O)NC(=O)S1 DTTSMAZTBFTAII-UHFFFAOYSA-N 0.000 description 1
- NPKHMGWGMDKIKM-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-(1,3-thiazolidin-5-ylmethyl)-3-(trifluoromethyl)phenoxy]phenyl]propanoate Chemical compound C1=CC(CC(N)C(=O)OC)=CC=C1OC(C=C1C(F)(F)F)=CC=C1CC1SCNC1 NPKHMGWGMDKIKM-UHFFFAOYSA-N 0.000 description 1
- PGUVBVMVOHNTGJ-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]-2-nitrophenoxy]phenyl]propanoate Chemical compound C1=CC(CC(N)C(=O)OC)=CC=C1OC(C(=C1)[N+]([O-])=O)=CC=C1CC1C(=O)NC(=O)O1 PGUVBVMVOHNTGJ-UHFFFAOYSA-N 0.000 description 1
- XMJVDOJWDCSGAM-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]-3,5-difluorophenoxy]phenyl]propanoate Chemical compound C1=CC(CC(N)C(=O)OC)=CC=C1OC(C=C1F)=CC(F)=C1CC1C(=O)NC(=O)O1 XMJVDOJWDCSGAM-UHFFFAOYSA-N 0.000 description 1
- WXOLLQHWOZXMKM-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]phenoxy]-2-methylphenyl]propanoate Chemical compound C1=C(C)C(CC(N)C(=O)OC)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)O1 WXOLLQHWOZXMKM-UHFFFAOYSA-N 0.000 description 1
- OOAGJTGMKGAQOI-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]phenoxy]phenyl]propanoate Chemical compound C1=CC(CC(N)C(=O)OC)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)O1 OOAGJTGMKGAQOI-UHFFFAOYSA-N 0.000 description 1
- BWVSFAQOCHIQKO-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-(trifluoromethyl)phenoxy]phenyl]propanoate Chemical compound C1=CC(CC(N)C(=O)OC)=CC=C1OC(C(=C1)C(F)(F)F)=CC=C1CC1C(=O)NC(=O)S1 BWVSFAQOCHIQKO-UHFFFAOYSA-N 0.000 description 1
- OHRGYUROFCVMNL-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-fluorophenoxy]phenyl]propanoate Chemical compound C1=CC(CC(N)C(=O)OC)=CC=C1OC(C(=C1)F)=CC=C1CC1C(=O)NC(=O)S1 OHRGYUROFCVMNL-UHFFFAOYSA-N 0.000 description 1
- JJBYDFLJMUHEMF-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methylphenoxy]phenyl]propanoate Chemical compound C1=CC(CC(N)C(=O)OC)=CC=C1OC(C(=C1)C)=CC=C1CC1C(=O)NC(=O)S1 JJBYDFLJMUHEMF-UHFFFAOYSA-N 0.000 description 1
- SJIUIVVHNVNIEV-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-3-fluorophenoxy]phenyl]propanoate Chemical compound C1=CC(CC(N)C(=O)OC)=CC=C1OC(C=C1F)=CC=C1CC1C(=O)NC(=O)S1 SJIUIVVHNVNIEV-UHFFFAOYSA-N 0.000 description 1
- GJGYTLHGCWICCL-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]-2-(trifluoromethyl)phenyl]propanoate Chemical compound C1=C(C(F)(F)F)C(CC(N)C(=O)OC)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GJGYTLHGCWICCL-UHFFFAOYSA-N 0.000 description 1
- SDZHNZRFCJBBOX-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]-3,5-difluorophenyl]propanoate Chemical compound FC1=CC(CC(N)C(=O)OC)=CC(F)=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 SDZHNZRFCJBBOX-UHFFFAOYSA-N 0.000 description 1
- USGKBRMYSUMVLX-UHFFFAOYSA-N methyl 2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]phenyl]propanoate;hydrochloride Chemical class Cl.C1=CC(CC(N)C(=O)OC)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 USGKBRMYSUMVLX-UHFFFAOYSA-N 0.000 description 1
- USOQPLZEWYDGCA-UHFFFAOYSA-N methyl 3-[4-[4-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]phenoxy]phenyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound C1=CC(CC(C(=O)OC)NC(=O)OC(C)(C)C)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)O1 USOQPLZEWYDGCA-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100001092 no hepatotoxicity Toxicity 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- RAIYODFGMLZUDF-UHFFFAOYSA-N piperidin-1-ium;acetate Chemical compound CC([O-])=O.C1CC[NH2+]CC1 RAIYODFGMLZUDF-UHFFFAOYSA-N 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910001023 sodium amalgam Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000000261 subcutaneous preadipocyte Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000003548 thiazolidines Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
x | AMINO ACID PHENOXY ETHERS
B Co This application claims the benefit of the earlier filing date of U.S. Provisional
Application No. 60/440,772 filed January 17, 2003, which is incorporated herein by reference. :
The. present invention relates to novel amino acid phenyl ethers for the treatment of immunological diseases, inflammation, obesity, hyperlipidemia, hypertension, neurological diseases and diabetes. ©. | oo
TE. Background of the invention Co
The principal elements of the immune system are macrophages or antigen-presenting cells, T cells and B cells. The role of other immune cells such as NK cells, basophils, mast . | cells and dendritic cells are known, but their role in primary immunologic disorders is uncertain. Macrophages are important mediators of both inflammation and providing the necessary "help" for T cell stimulation and proliferation. Most importantly macrophages make IL 1, IL 12 and TNF-a all of which are potent pro-inflammatory molecules and also provide help for T cells. In addition, activation of macrophages results in the induction of enzymes, such as cyclooxygenase II (COX-2), inducible nitric oxide synthase (iNOS) and production of free radicals capable of damaging normal cells. Many factors activate macrophages, including bacterial products, superantigens and interferon gamma (IFN 7). Itis believed that phosphotyrosine kinases (PTKs) and other undefined cellular kinases are involved in the activation process.
Cytokines are molecules secreted by immune cells that are important in mediating immune responses. Cytokine production may lead to the secretion of other cytokines, altered cellular function, cell division or differentiation. Inflammation is the normal response to . injury or infection. However, in inflammatory diseases such as rheumatoid arthritis, pathologic inflammatory processes can lead to morbidity and mortality. The cytokine tumor necrosis factor-alpha (TNF-a) plays a central role in the inflammatory response and has been targeted as a point of intervention in inflammatory disease. TNF-a. is a polypeptide hormone released by activated macrophages and other. cells. At low concentrations, TNF-a participates in the protective inflammatory response by activating leukocytes and promoting their migration to extravascular sites of inflammation (Moser et al.,'J Clin Invest, 83:444- 55,1989). At higher concentrations, TNF-o. can act as a potent pyrogen and induce the production of other pro-inflammatory cytokines (Haworth et al., Eur J Iramunol, 21:2575-79, 1991; Brennan et al., Lancet, 2:244-7, 1989). TNF-a. also stimulates the synthesis of acute- phase proteins. In rheumatoid arthritis, a chronic and progressive inflammatory disease "affecting about 1% of the adult U.S. population, TNF-o. mediates the cytokine cascade that leads to joint damage and destruction (Arend et al., Arthritis Rheum, 38:151-60,1995).
Inhibitors of TNF-a, including soluble TNF receptors (etanercept) (Goldenberg, Clin Ther, 21:75-87, 1999) and anti-TNF-o antibody (infliximab) (Luong et al., Ann Pharmacother, 34:743-60, 2000), have recently been approved by the U.S. Food and Drug Administration (FDA) as agents for the treatment of rheumatoid arthritis. ‘
Elevated levels of TNF-a have also been implicated in many other disorders and disease conditions, including cachexia, septic shock syndrome, osteoarthritis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis etc. .
Excessive production of IL-6 is implicated in several disease states, it is highly desirable to develop compounds that inhibit IL-6 secretion.
The cytokine IL-1 also participates in the inflammatory response. It stimulates thymocyte proliferation, fibroblast growth factor activity, and the release of prostaglandin from synovial cells.
Elevated or unregulated levels of the cytokine IL-1B have been associated with a number of inflammatory diseases and other disease states, including but not limited to adult respiratory distress syndrome, allergy, Alzheimer's disease etc.
Since overproduction of IL-1P is associated with numerous disease conditions, it is desirable to develop compounds that inhibit the production or activity of IL-1f.
It will be appreciated from the foregoing that, while there have been extensive prior efforts to provide compounds for inhibiting, for example, TNF-a, IL-1, IL-6, COX-2 or other agents considered responsible for immune response, inflammation or inflammatory diseases, e.g. arthritis, there still remains a need for new and improved compounds for effectively treating or inhibiting such diseases.
There appears to be a correlation of TNF-a to. adipogenesis (obesity) and other metabolic disorders such as diabetes mellitus. Although, in the past two decades there has been an explosive increase in number of people diagnosed with diabetes worldwide [Amos © A, McCaty, D,, Zimmet, P. (1997) Diabetic Med. 14, S1-S85; King, H., Aubert, R.,
Herman, W. (1998) Disbétes Care, 21, 1414-1431], there has been relatively little development of new therapeutics for the treatment of diabetes and its associated conditions 5. [Moller, D.E. (2001) Nature 414, 821-827). Diabetes exists in two types: insulin dependent
Type-1 and non-Insulin dependent (insulin-resistant) Type-Il. Type-II insulin-resistant diabetes mellitus accounts for 90-95% of all diabetes. This syndromic metabolic disorder currently affects more than 150 million people worldwide and is projected to grow to 300 million by year 2005 [Amos, A., McCarty, D., Zimmet, P. (1997) Diabetic Med. 14, S1-S85;
Kopelman, P.G. Hitaman, G.A. (1998) Lancet, 352, SIV5). The main force driving this increase in incidence of type II diabetes is an increase in obesity, the single most important contribution to the pathogenesis of type II diabetes [Kopelman, P.G., Hitaman, G.A. (1998)
Lancet, 352, SIVS).
At present, therapy for type II diabetes relies mainly on several approaches intended to reduce the hyperglycemia itself. These are: sulfonylureas and related insulin secretogens that are known to release more insulin from pancreatic B cells; metformin, that acts to reduce hepatic glucose production; peroxisome proliferator-activated receptor (PPAR) agonists that enhances insulin action; a-glucosidase inhibitors that slow down absorption of glucose from the gut; and insulin itself, that suppresses glucose production and augments glucose utilization (summarized in table I below). All of these therapies have limited efficacy, limited tolerability and significant mechanism-based side effects. Of particular concer is the tendency for most treatment to enhance body weight gain. Several current treatments for type II diabetes are associated with episodes of hypoglycemia, and few of the available therapies adequately address underlying defects such as obesity and a phenomenon known as insulin resistance. Among these oral medications, sulfonylureas represent the oldest and widely used form of treatment. Many patients who respond to sulfonylureas initially become refractory to the treatment over time (secondary failure). Besides glucose level and obesity, type II diabetes is now linked with high level of triglycerides and cholesterol. Therefore, there is a need for new classes of drugs addressing the underlying issue of metabolic defects
(increasingly known as Syndrome-X) such as obesity, hyperglycemia and hyperlipidemic conditions to address type II diabetes and its associated condition.
Table 1: Current Therapeutic agents for Type II Diabetes
Drug class Delivery Molecular Target Site of Action Adverse Events — ee —— ee —————— em . Insulin Intramuscular Insulin receptor Liver, Muscle, Fat Weight gain
Hypoglycemia =
Sulfonylureas Oral SU receptors Pancreatic 8 cells Weight gain (glibenclamide) K+/ATP channel "Hypoglycemia (repaglinide) . : (nateglinide)
Metformin Oral Unknown Liver (muscle) . Gl disturbance (biguanides) Lactic acidosis a-Glucosidase Oral a-Glucosidase Intestine GI disturbance
Inhibitors . (Acarbose)
PPAR-agonist Oral PPAR-gammma Fat, Muscle, Liver Weight gain (Rosiglitazone) Anaemia (Pioglitazone) Qedema ee ———————— ee ———— eee
The present invention, relates to novel amino acid phenyl ethers of formula (I)
R2 R3 R4 [Py yA lo) x-A~y ; Na 0) their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, wherein - --- represents optional double bond; Y represents oxygen, sulfur or NR, wherein R represents ] hydrogen or alkyl; Z represents oxygen or sulfur; Rj, Rz, R3 and Rq may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, - alkoxy group; A represents a bond or substituted or unsubstituted aryl, heterocyclyl or heteroaryl ring; X represents an alpha amino carboxylic acid or its derivatives bonded to A or
Y through its alpha side chain. - The present invention also relates to a process for the preparation of the above said : novel compounds, their analogs, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable . solvates, novel intermediates and pharmaceutical compositions containing them. Tautomeric forms are isomeric forms. which exists in a state of equilibrium capable of reacting according to either form. Stereoisomers include configurational isomers, such as cis- and trans- double bonds, as well as optically active isomers having different spatial arrangements of their atoms. Polymorphs are molecules which can crystallize in two or more forms. Solvates are molecular or ionic complexes of molecules or ions of solvent with those of a solute. An alpha-amino carboxylic acid includes, but is not limited to, naturally-occurring amino acids.
The alpha side chain is a group, including hydrogen, covalently bonded to’the alpha carbon of an alpha-amino carboxylic acid. Analogs include those compounds which differ by substitution of an oxygen, sulfur, nitrogen or carbon atom in place of such an atom. Analogs also include atoms of the same family of the Periodic Table, such as F, Cl, Br, I, As.
Derivatives include compounds resulting from routine functionalizing of atoms, such as, derivatives found by protecting amino or carboxyl groups by carboxylation or esterification, Ce respectively.
The compounds of the present invention are effective in lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels and are useful in the treatment and / or prophylaxis of diabetes. The compounds of the present invention are effective in treatment of obesity, inflammation, autoimmune diseases such as such as multiple sclerosis and rheumatoid arthritis. Surprisingly, these compounds increase the leptin level and have no liver toxicity.
Furthermore, the compounds of the present invention are useful for the treatment of disorders associated with insulin resistance, such as polycystic ovary syndrome, as well as a0 hyperlipidemia, coronary artery disease and peripheral vascular disease, and for the treatment of inflammation and immunological diseases, particularly those mediated: by cytokines such as TNF-a, IL-1, IL-6, IL-1p and cyclooxygenase such as COX-2. :
Brief Description of figures | : : EE
Figure 1 shows that the compounds in Example 1 lower pro-inflammatory cytokines in : "human macrophage cells.
Figure 2 shows efficacy of compound 2 in Example 1 in an animal model of inflammation.
Figure 3 shows efficacy of compounds 1 and 2 in Example 1 in an animal model of autoimmunity. ’
Figure 4 represents schematic illustration of various cytokines and their role in management of a number of inflammatory and autoimmune diseases. . Figure 5 is a schematic illustration of how TNFa is linked to various metabolic disorders besides its inflammatory and autoimmune properties. Co
Figure 6 shows the blood glucose lowering effect of compound in Example 1 in ob/ob and db/db mice. oC
Figure 7 shows the effect of compounds 1 and 2 in Example 1 in weight gain reduction in an animal model of obesity. .
Figure 8 shows the effect of compound2 in Example 1 an insulin sensitizing and lipid : lowering activity.
Figure 9 shows the effect of lipid accumulation in human preadipocytes when treated with various dosages of a compound of the invention compared to rosiglitazone.
In an embodiment of the present invention, the groups represented by R;, Ry, Rj and
Ry are selected from hydrogen, halogen such as fluorine, chlorine, bromine or iodine; hydroxy, nitro, cyano, formyl, amino, linear or branched, substituted or unsubstituted (Cy-
Ci2)alkyl group such as methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl, hexyl, octyl, nonyl and the like; substituted or unsubstituted (C1-C2)alkoxy group such as methoxy, ethoxy, propoxy, butoxy and the like.
In an embodiment of the present invention, the group represented by A is selected "from aryl such as phenyl, naphthyl, and the like; heteroaryl ring such as pyridyl, pyrrolyl,
; thiazolyl, indolyl, imidazolyl, furyl and the like; heterocyclyl ring such as piperzine, : morpholine, piperidine, pyrrolidine and the like. “The group A may be mono, di or tr substituted and the substituents are selected from halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, haloalkyl, alkoxy, haloalkoxy and the like.
In an embodiment of the present invention, the amino acid and side chain represented by X, X-A or X-A-Y is selected from alanine, glycine, arginine, asparagine, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, ornithine, proline, serine, threonine, tryptophan, tyrosine and the like, which may be substituted or unsubstituted and their derivatives such as ester and amides of carboxylic acid. The preferred substituents are selected from halogen, alkyl, alkoxy, aryl, heteroaryl, amino and the like.
The amino acid X-A-Y preferably represents substituted or unsubstituted arginine, asparagine, cysteine, glutamine, histidine, lysine, methionine, omithine, proline, serine, threonine, tryptophan, tyrosine and their derivatives. The group X-A also preferably represents alanine, glycine, isoleucine, leucine and their derivatives. In another embodiment
A represents a substituted or unsubstituted alkyl, heterocyclyl or heteroaryl ring.
In another embodiment, Z is sulfur and Y is oxygen. Preferably, R, through R, are hydrogen.
Pharmaceutically acceptable salts forming part of this invention include base addition salts such as alkali metal salts like Li, Na, and K salts, alkaline earth metal salts like Ca and
Mg salts, salts of organic bases such as lysine, arginine, guanidine, diethanolamine, choline and the like, ammonium or substituted ammonium salts. Salts may include acid addition salts which are, sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, " tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, ketoglutarates and the like. Pharmaceutically acceptable solvates may be hydrates or comprising other solvents of crystallization such as alcohols.
Preferably, the present invention relates to novel amino acid phenyl ethers of formula
M
R2 R3 4 ge 0)
RN their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, wherein - --- represents optional double bond; Y represents oxygen, sulfur or NR, wherein R represents - hydrogen or alkyl; Z represents oxygen or sulfur; Ry, Ry, R3 and Rs may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents substituted or unsubstituted aryl; X' represents an alpha amino carboxylic acid or its derivatives bonded through its alpha side chain to A.
More preferably, the present invention relates to novel amino acid phenyl ethers of formula (I)
R2 Ra R4 rl =o mn
RM HN their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, wherein - . —- represents optional double bond; Y represents oxygen, sulfur or NR, wherein R represents hydrogen or alkyl; Z represents oxygen or sulfur; Rj, Rs, Rs and R; may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents substituted or unsubstituted phenyl; X represents alanine or its derivatives bonded to A through its alpha methyl group.
Particularly useful compounds according to the invention include: 5.[4-(4~(2- Amino-2-carboxyethyl)phenoxy)benzilidene]thiazolidin-2,4-dione or its salts ; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)benzilidene]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)benzyl]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)benzyl]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)benzilideneJoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)benzilidene]oxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)benzyl]oxazolidin-2,4-dione or its salts;
3 5-[4-(4-(2- Amino-2-methoxycarbonylethyl)phenoxy)benzyl]oxazolidin-2,4-dione or its salts; 5.[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,6-diffuorobenzilideneloxezolidin-2,4-dione or its salts; : 5-{4-(4-(2- Amino-2-methoxycarbonylethyl)phenoxy)-2,6-diflucrobenzilidene] oxazolidin- 2,4-dione or its salts; : 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,6-difluorobenzyljoxazolidin-2,4-dione or its - salts; : 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,6-difluorobenzyl] oxazolidin-2,4- dione orits salts; : Co : 5-[4-(4-(2- Amino-2-carboxyethyl)phenoxy)-2,6-diflucrobenzilidene]thiazolidin-2,4-dione or its salts; : } 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,6-difluorobenzilidene] thiazolidin- 2,4-dione or its salts; : : 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,6-difluorobenzyljthiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,6-difluorobenzyl] ~~ thiazolidin-2,4- dione or its salts;
5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,3-difluorobenzilidene]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2- Amino-2-methoxycarbonylethyl)phenoxy)-2,3-difluorobenzilidene] ~~ thiazolidin- 2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,3-difluorobenzyl]thiazolidin-2,4-dione or its salts; 5-[4-(4~(2- Amino-2-methoxycarbonylethyl)phenoxy)-2,3-difluorobenzyl] thiazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,3-difluorobenzilidene]oxazolidin-2,4-dione or its salts;
5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,3-diflucrobenzilidene] oxazolidin-
2,4-dione or its salts; oo
. 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,3-difluorobenzyljoxazolidin-2,4-dione or its salts; | . 7
5. [4-(4-(2-Amino:2-methoxycarbonylethylphenoxy)-2,3-difluorobenzyl] oxazolidin-2,4- "dione or its salts;
5.[4-(4-(2- Amino-2-carboxyethyl)phenoxy)-3-methylbenzilidene]oxazolidin-2,4-dione or its salts;
5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-methylbenzilidene] oxazolidin-2,4- dione or its salts; 5.[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-methylbenzylJoxazolidin-2,4-dione or its salts;
© 5.[4-(4-(2- Amino-2-methoxycarbonylethyl)phenoxy)-3-methylbenzyljoxazolidin-2,4-dione or its salts;
5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-methylbenzilidene]thiazolidin-2,4-dione or its salts; : 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-methylbenzilidene] thiazolidin-2,4- dione or its salts;
5-[4-(4-(2- Amino-2-carboxyethyl)phenoxy)-3-methylbenzyl]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-methylbenzyl]thiazolidin-2,4-dione or its salts; :
5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-nitrobenzilidene]thiazolidin-2,4-dione or its salts; 5-{4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-nitrobenzilidene] thiazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-nitrobenzyl]thiazolidin-2,4-dione or its salts;
5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-nitrobenzyl]thiazolidin-2,4-dione or © ts salts; . 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-nitrobenzilidene]oxazolidin-2,4-dione or its salts; : : 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-nitrobenzilidene] oxazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3 -nitrobenzyl]oxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-nitrobenzyl]oxazolidin-2,4-dione or its salts; Lo : 5-[4-(4-(2- Amino-2-carboxyethyl)phenoxy)-3-aminobenzilidene]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-aminobenzilidene] thiazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-aminobenzyl]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2- Amino-2-methoxycarbonylethyl)phenoxy)-3-aminobenzyl]thiazolidin-2,4-dione or its salts; : 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-aminobenzilidene]oxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-aminobenzilidene] ~~ oxazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-aminobenzylJoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-aminobenzyl]oxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2-fluorobenzilidene]thiazolidin-2,4-dione or its salts; : 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2-fluorobenzilidene] thiazolidin-2,4- dione or its salts;
5.[4-(4-(2- Amino-2-carboxyethyl)phenoxy)-2-flucrobenzyl]thiazolidin-2,4-dione or its salts;
5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2-fluorobenzyl]thiazolidin-2,4-dione or its salts; Co
§ 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2-fluorobenzilideneJoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2-fluorobenzilidene] = oxazolidin-2,4- dione or its salts; : . 5-[4-(4-(2- Amino-2-carboxyethyl)phenoxy)-2-flucrobenzyljoxazolidin-2,4-dione or its salts ;
5-[4-(4-(2- Amino-2-methoxycarbonylethyl)phenoxy)-2-fluorobenzy!joxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-fluorobenzilidene]thiazolidin-2,4-dione or its salts; :
5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-fluorobenzilidene] thiazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-fluorobenzyl]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-fluorobenzyl]thiazolidin-2,4-dione or its salts;
5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-fluorobenzilidene]oxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-fluorobenzilidene] oxazolidin-2,4- dione or its salts;
5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-fluorobenzyl]oxazolidin-2,4-dione or its salts ; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-fluorobenzyljoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2-trifluoromethylbenzilidene] ~~ thiazolidin-2,4- dione or its salts;
5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2-trifluoromethylbenzilidene]
. thiazolidin-2,4-dione or its salts; : §.[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2-triflucromethylbenzyl]thiazolidin-2,4-dione or its salts; Co 5-[4-(4-(2- Amino-2-methoxycarbonylethyl)phenoxy)-2-trifluoromethylbenzyl] thiazolidin-
. 2,4-dione or its salts; So 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2-trifluoromethylbenzilidene] oxazolidin-2,4- dione or its salts; .
5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2-trifluoromethylbenzilidene] oxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2-trifluoromethylbenzylJoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2-trifluoromethylbenzyl] oxazolidin-
2,4-dione or its salts; : : 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-trifluoromethylbenzilidene] thiazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-trifluoromethylbenzilidene] :
thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-trifluoromethylbenzyl]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-trifluoromethylbenzyl] thiazolidin- 2,4-dione or its salts;
- 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-trifluoromethylbenzilidene] ~~ oxazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-triflucromethylbenzilidene] oxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-trifluoromethylbenzyljoxazolidin-2,4-dione or its salts;
. 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-trifluoromethylbenzyl] ~ oxazolidin- 2,4-dione or its salts; Co 5-[4-(4-(2- Amino-2-carboxyethyl)-2,6-difluorophenoxy)benzilidene]oxazolidin-2,4-dione or its salts; | : 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2,6-difluorophenoxy)benzilidene] ~~ oxazolidin- ~~ 2,4-dione or its salts 5-[4-(4-(2-Amino-2-carboxyethyl)-2,6-difluorophenoxy)benzyloxazolidin-2,4-dione or its salts; | : 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2,6-difluorophenoxy)benzyl] oxazolidin-2,4- dione or its salts; ’ I 5-[4-(4-(2-Amino-2-carboxyethyl)-2,6-difluorophenoxy)benzilidene]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2,6-difluorophenoxy)benzilidene] thiazolidin-
2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-2,6-difluorophenoxy)benzyljthiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2,6-difluorophenoxy)benzyl] thiazolidin-2,4- dione or its salts;
5-[4-(4-(2- Amino-2-carboxyethyl)-2,3-difluorophenoxy)benzilidene]thiazolidin-2,4-dione or its salts 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2,3-difluorophenoxy)benzilidene] thiazolidin- 2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-2,3-difluorophenoxy)benzyljthiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2,3-difluorophenoxy)benzyl] thiazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-2,3-diflucrophenoxy)benzilidene]oxazolidin-2,4-dione or its salts;
5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2,3-diflucrophenoxy)benzilidene]-oxazolidin- : 2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-2,3-difluorophenoxy)benzylJoxazolidin-2,4-dione or its salts; | oo : 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2,3-difluorophenoxy)benzyl} oxazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-3-methylphenoxy)benzilidene]oxazolidin-2,4-dione or its salts; . 5.[4-(4~(2- Amino-2-methoxycarbonylethyl)-3-methylphenoxy)benzilidene] oxazolidin-2,4- ‘dione or its salts; 5-[4-(4-(2- Amino-2-carboxyethyl)-3-methylphenoxy)benzyl]oxazolidin-2,4-dione or its salts; 5-[4-(4-(2- Amino-2-methoxycarbonylethyl)-3-methylphenoxy)benzyl]oxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-3-methylphenoxy)benzilidene]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2- Amino-2-methoxycarbonylethyl)-3-methylphenoxy)benzilidene] thiazolidin-2,4- dione or its salts; 5.[4-(4-(2-Amino-2-carboxyethyl)-3-methylphenoxy)benzyl]thiazolidin-2,4-dione or its salts; 5.[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-methylphenoxy)benzyl]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-3-nitrophenoxy)benzilidene]thiazolidin-2,4-dione or its salts; . 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-nitrophenoxy)benzilidene] thiazolidin-2,4- dione or its salts; : 5-[4-(4-(2-Amino-2-carboxyethyl)-3-nitrophenoxy)benzyl]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-nitrophenoxy)benzyljthiazolidin-2,4-dione or its salts;
oo 5-[4-(4-(2-Amino-2-carboxyethyl)-3-nitrophenoxy)benzilidene]oxazolidin-2,4-dione or its } salts; 5-[4-(4-(2- Amino-2-methoxycarbonylethyl)-3-nitrophenoxy)benzilidene} oxazolidin-2,4- dione or its salts; | :
5.[4~(4-(2- Amino-2-carboxyethyl)-3-nitrophenoxy)benzyljoxazolidin-2,4-dione or its salts; 5.[4-(4-(2- Amino-2-methoxycarbonylethyl)-3-nitrophenoxy)benzyl]oxazolidin-2,4-dione or its salts; 5.[4-(4-(2-Amino-2-carboxyethyl)-3-aminophenoxy)benzilidene]thiazolidin-2,4-dione or its -
salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-aminophenoxy)benzilidene] thiazolidin-2,4- dione or its salts; : 5-[4-(4-(2-Amino-2-carboxyethyl)-3-aminophenoxy)benzyl]thiazolidin-2,4-dione or its salts; 5-[4-(4~(2-Amino-2-methoxycarbonylethyl)-3-aminophenoxy)benzyl]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2- Amino-2-carboxyethyl)-3-aminophenoxy)benzilideneJoxazolidin-2,4-dione or its salts; . 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-aminophenoxy)benzilidene] oxazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-3-aminophenoxy)benzyl]oxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-aminophenoxy)benzylloxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-2-fluorophenoxy)benzilidene]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2-fluorophenoxy)benzilidene]- thiazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-2-fluorophenoxy)benzyl]thi azolidin-2,4-dione or its salts; 5.[4-(4~(2- Amino-2-methoxycarbonylethyl)-2-flucrophenoxy)benzyl]thiazolidin-2,4-dione or its salts;
5-[4-(4-(2-Amino-2-carboxyethyl)-2-fluorophenoxy)benzilidene]oxazolidin-2,4-dione or its salts; §-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2-fluorophenoxy)benzilidene] oxazolidin-2,4- dione or its salts; : 5 Co 5 5-[4-(4-(2-Amino-2-carboxyethyl)-2-fluorophenoxy)benzyl]oxazolidin-2,4-dione or its salts; 5-{4-(4-(2-Amino-2-methoxycarbonylethy!)-2-fluorophenoxy)benzyljoxazolidin-2,4-dione or : its salts; : : 5.[4-(4-(2-Amino-2-carboxyethy])-3-fluorophenoxy)benzilidene]thiazolidin-2,4-dione or its “10 salts; : 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-fluorophenoxy)benzilidene] thiazolidin-2,4- dione or its salts; : 5-[4-(4-(2-Amino-2-carboxyethyl)-3-fluorophenoxy)benzyl]thiazolidin-2,4-dione or its salts; 5.[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-fluorophenoxy)benzylJthiazolidin-2,4-dione or its salts; 5.[4-(4-(2-Amino-2-carboxyethyl)-3-fluorophenoxy)benzilidene]oxazolidin-2,4-dione or its salts; 5.[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-fluorophenoxy)benzilidene] oxazolidin-2,4- dione or its salts; 20° 5-[4-(4-(2-Amino-2-carboxyethyl)-3-fluorophenoiy)benzyl]oxazolidin-2,4-dione or its salts; © 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-fluorophenoxy)benzyljoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-2-trifluoromethylphenoxy)benzilidene] thiazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2-trifluoromethylphenoxy) benzilidene) thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-2-trifluoromethylphenoxy)benzyl]thiazolidin-2,4-dione or its salts; - 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2-trifluoromethylphenoxy)benzyl] thiazolidin- 2,4-dione or its salts;
: 5-[4-(4-(2-Amino-2-carboxyethyl)-2-trifluoromethylphenoxy)benzilidene] oxazolidin-2,4- ~~ dione or its salts; oo 5-[4-(4-(2-Amino-2-methoxycarbonylethy!)-2-triflucromethylphenoxy) benzilidene] oxazolidin-2,4-dione or its salts; } : Co 5-[4~(4-(2-Amino-2-carboxyethyl)-2-riflaoromethylphenoxy)benzylJoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2-trifluoromethylphenoxy)benzyl] oxazolidin- 2,4-dione or its salts; oo -
5-[4-(4-(2-Amino-2-carboxyethyl)-3-trifluoromethylphenoxy)benzilidene] thiazolidin-2,4-
dione or its salts;
5-[4-(4-(2-Amino-2-methoxycarbonylethy!)-3-trifluoromethylphenoxy) benzilidene) thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethy!)-3-trifluoromethylphenoxy)benzyljthiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-trifluoromethylphenoxy)benzyl] thiazolidin- 2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-3-trifluoromethylphenoxy)benzilidene] oxazolidin-2,4- dione or its salts;
5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-trifluoromethylphenoxy) benzilidene] oxazolidin-2,4-dione or its salts; 5.[4-(4-(2-Amino-2-carboxyethyl)-3-trifluoromethylphenoxy)benzyljoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-trifluoromethylphenoxy)benzyl] oxazolidin-
2,4-dione or its salts; 5-[4-(4-(2-t-butoxycarbonylamino-2-methoxycarbonylethyl)phenoxy) benzilidene] thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-t-butoxycarbonylamino-2-methoxycarbonylethyl)phenoxy) benzyljthiazolidin-2,4-
dione or its salts;
- 5.[4-(4-(2-t-butoxycarbonylamino-2-methoxycarbonylethyl)phienoxy) benzilidene] ~ oxazolidin-2,4-dione or its salts; : : : 5-[4-(4-(2-t-butoxycarbonylamino-2-methoxycarbonylethyl)phenoxy) benzyl]oxazolidin-2,4- dione or its salts. : | BN oo 5-[4-(4-(2-t-butoxycarbonylamino-2-carboxyethyl)phenoxy) benzilidenelthiazolidin-2,4- dione or its salts; 5-[4-(4-(2-t-butoxycarbonylamino-2-carboxyethyl)phenoxy)benzyl]thiazolidin-2,4-dione or its salts; 3 : . : 5.[4-(4-(2-t-butoxycarbonylamino-2-carboxyethyl)phenoxy) benzilidene]oxazolidin-2,4- dione or its salts and 5-[4-(4-(2-t-butoxycarbonylamino-2-carboxyethyl)phenoxy)benzylloxazolidin-2,4-dione or its salts.
Co Ry x Ay xy 7 NH il SE al el
No.
COOH | or HH
NT CH, 2 ~ COOCH; - or HH SE
HN CH, : COOH H
HN Hy JJ 4 COOCH;4 Jou HH 7H
HAN” CH
COOH HH or or
GOOCH, HH
HAN CHy cr
H,N” “CH,
COOCH;Z PTE
HCH or
COOH >F
COOCH, 3F, Hq
HN CHy or 6-F
COOH 2-F, [2H
HN CH, or 6-F
H,N” “CH, 6-F 13 COOH SF TH
HN” CH, 6-F
COOH 2-F, 2H
PN 6-F
HN" CH,
COOCH;S "2-F, S
PN 6-F
HN” “CH, : 17 COOH 2F,
PN 3F
HN” "CHp : COOCH; 2-F,
PN 3.F
HN" “CH,
HN CH, 3.F
Poul Fo 2
HNC 3.F 21 COOH Jor 2-F,
HN CH, 3.F 22 COOCHs3; or 2-F,
HN CH, 3.F 23 COOH Jou 2-F,
HN CH, 3F 24 COOCH;3 2F, 2H x or 3F
HN" CH,
H NCH or 2 2 26 COOCH3; 3-Me aN CH AT 27 COOH 3 Vie - pos
HN” “CH, 28 foe or 3-Me |2H
HoN” “CHa 29 foe or 3-Me
HN” “CH,
COOCHj3 Jou 3-Me~
HN CH, 31 COOH 7H aN cH, jos 32 foo or 3-Me | 2H
HN” “CH;
So | HN CH
HN CH, “COOH Jot 3-NO, [2H co
HN CH,
J el PS ou i dl i
HN CH
37 COOH Jo 3-NO; ’ HAN CH, C 38 : COOCH;g : or 3-NO, H .
HN CH,
COOH Jou 3-NO; {2H
HN CH, 40 foots Jou 3-NO; | 2H
HN” “CHy 41 goon Jou 3-NH,
HoN CH, ’ a2 foocts or 3-NH, |H
HN” “CH; 43 goo 3-NH; | 2H
HN” “CH, J® 44 goocks or 3-NH; | 2H
HoN CH, 45 COOH 3-NH; |H
COOCH; 3-NH,
HN CH, jos 47 goon jor 3-NH, | 2H
HN~ “CHa, 48 foocts Jos 3-NH; {2H
HN” CH, for 2-F H 50 foots or 2-F H
HN" “CH;
31 COOH o 2F ©
HANH, 52 COOCH;, jot 2-F co
HAN” CH, . — :
HN CH,
COOH Jou 2-F ©]
HN CH
56 COOCH;, Jor 2F [2H
HN CH, : 57 COOH IF 58 COOCH; 3-F . COOH 3-F
HNC, jos
COOCH3 IF : a iol
COOH 3F
HN CH, Jol 62 COOCH3 3-F ah Ch jos 63 jad Jor IF 78
HN” CH,
COOCH; 3-F 2H
LT bl >
COOCH;4 2-CF; 67 or or 2-CF; | 2H :
HN" “CH; : foocts 2-CF; |2H
HN” CH, J §
SS ol i ll oo HN CH,
HAN Ch, _ Jo
HN CH, fl Soul ol il
HN CH, : : 73 COOH | Jol 3-CF3
HN CH, 1 74 COOCH; : or 3.CF; | H
HINT CH, ’ 75 | COOH or 3-CF; | 2H
HN CH, 76 COOCH;Z or 3-CF; |2H
HINT CH, - 77 FH or 3-CF;
HN” “CH, 78 COOCH;3 3-CF; 79 goon or 3-CF; | 2H
HN" CH, 80 foocks or 3-CF; | 2H
HoN~ “CH,
COOH F H,H H
HN CH Jot
F
82 GoocH F AH 8
HoN”~ CH, Jot
F
83 COOH F HH 2H 2 2
F
~~ COOCHs F H
HoN Aen, Jos
F
85 goon F
HN” “CH, or . §i00cHs F HH
HN” “CH, or
F
87 COOH F 2H
Co NCH, or . . 88 COOCH; F
HNC Jou
F
COOH HH
F
COOCH,
F
COOH : HH 2H . F i 92 “Fook: HH [2H
HN” “CH, LL :
F
03 COOH HH
HN CH LC
F
COOCH3 HA
F
95 or HH |2H : . F R foocrs H,H 2H
HN” CH, F
F
: 97 COOH : 2 HH |H oo HN CH,
COOCH; HH |H
HN CH, E . -£
COOH 2H oon ol . COOCH;Z Co HH 2H noc Lr
COOH H,H H
HN CH jos . F } 102 foocks HH
F___ 103 goer HB 5H
F
COOCH; HH 2H
F
105 COOH "HH |H
Bele 2 2
CHs
COOCH; HH |H
HAN CH LT
CH, 107 goon H,H 7H
CHs
HN CH, Lr
CH,
COOH HH
HN GH, or
CH,
COOCH; HH . HN CH or p3
CHa
COOH 2H
HNP CH, jo
CH, . 112 “Gooch, ZH
HoN~ “CHy :
CH, 113 COOH
HN CH jog
NO,
COOCH;3
HN CH jo
NO, 115 goon HH |24
HoN™ CH; jos
NO, co 116 oct 2H
HaN~ “CHa jo
NO, 117 COOH
HN Aon, jo
NO, foosts HH
Bde
NO, oon H,H 2H
HN” CH
NO,
Lo 120 | COOCH; HH [2H
Ce
RE NO, 121 COOH : H,H H
MHEECdEnEN
A, 122 |. COOCH; HH |H
MEomrasuael : NH, 123 | COOH 7H
MEAN
NH, 124 | COOCH; HH 7H ee AE - NH; 125 COOH aH
MEcmCa
NH, 126 COOCH; HH TH
MERC
NH, 127 COOH EA ER
Ce PE
NH, 128 COOCH3 HH 7H
MERE)
NH, 129 COOH AH TH
EYE ved ils 130 COOCH; oH we LCC TT 131 COOH TH [2H
Ill PE Il 132 COOCH;, HH 5H
Bl SS veo i al ll
133 JooH H,H
HoN™ "CHg F 134 COOCHS3 - Ha CH, CL : sa . 135 goon Jol HH . HoN CH, F 136 qoocts
H2N CHa ACC F ili 137 Ja
F
138 foocks H,H
HN CH» i g
F : - 139 fon :
HN™ "CHa Lr : F
HoN™ "CHa
F
141 oH ’
F
142 o0cH, HH
HN“ “CHa
I . 143 or HH 2H
HN” CH,
F
144 fooens H,H 2H
HoN CH, )
L . foocrs H,H H
HN” “CHg CF,
147 oor iE Jot HH |2H
HN" CH CFs
GoocH, Jot 2H
HaN’ CH, CF, 149 | goon Jot HH
HN” “CHy' CFs
JO CI
HoN” “CH, 1 CFs 151 . goon or 2H
HN” CH, CF, 152 qooch Jou 2H
HN” CH, oF 153 goon HH 51
HN” “CH, : . CFs 154 “GOOCH I A
HoNT CH,
CFs 155 goon 7H
HN" “CH,
CFs 156 §o0cH 5H
HN” “CH,
CF, 157 oon HH
HN” CH, . CF 158 fooch HA Hd
HN” “CH,
CFs 159 on HH TH
HN” “CHy
CF;
COOCH; HH
Bare
CFs
H,H 161 CH, 1 foocrs Joi \
Hac—-0 N“ ch, - : CHa 2H 162 CHa 1 foocks Jou HH
Heo" Neh, chy; H 163 O COOCH;, - CHa JL or
HeC—-0 N" CH,
CH, 164 CH, Jig Foot or 2H
HeC—0" "NCH, |.
CH; H 165 0 COOH ep ET
HaC—07 NCH, cH, MH 0 COOH 2H nk ET
HyC——0 N" CH,
CHs 167 CH, 1 Joon Jou H,H
HaC—0 N" CH,
CHa 168 CH, Jil fon Jou HH |2H
HC—0" “NCH,
CHy H
: . | Preferred salts for the list of compounds above are hydrochloride, hydrobromide, : | sodium, potassium or magnesium. :
According to another feature of the present invention, there is provided a process for the preparation of compounds of formula (I), wherein —- represents a bond and all other symbols are as defined earlier, as shown in scheme- I
Ra wo i” , :
Xr AYR 4 oo a ME Sad a) FU amy ag FR | oH rz. 3 ra R2 R4 z 4
RN - Rt oN (0) (nd)
Scheme-I
The reaction of compound of formula (IIIa) wherein X; represents a protected alpha amino carboxylic acid group and all other symbols are as defined earlier with the compound of formula (IIIb) wherein L represents a nucleophilic aromatic substitution leaving group, and all other symbols are as defined earlier to produce a compound of formula (IIlc) may be carried out in the presence of solvents such as THF, DMF, DMSO, DME and the like or mixtures of solvents may be used. The reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as Nj, Ar or He. The reaction may be effected in the presence of a base such as K;COs, Na,COs, NaH or mixtures thereof, The reaction temperature may range from 20 °C to 150 °C, preferably at a temperature in the range of 30 °C to 100 °C. The duration of the reaction may range from 1 to 24 hours, preferably from 2 to 6 hours.
The conventional protecting groups used are those that can be easily removed and are selected from t-Boc, CBz, F-moc, etc.
The reaction of the compound of the general formula (I1lc) with 2,4-thiazolidinedione or 2,4-oxazolidinedione to yield a compound of formula (111d) may be carried out neat in the presence of sodium acetate or in the presence of a solvent such as benzene, toluene, methoxyethanol or mixtures thereof. The reaction temperature may range from 80 °C to 180 °C, when the reaction is carried out neat in the presence of sodium acetate. Suitable catalyst such as piperidinium acetate or benzoate, sodium acetate or mixtures of catalysts may also be employed. Sodium acetate can be used in the presence of solvent, but it is preferred that sodium acetate is used neat. The water produced in the reaction may be removed, for example, by using Dean Stark water separator or by using water absorbing agents like molecular sieves. .
The deprotection of amino acid group of formula (111d) to yield compound of formula (I) may be carried out using acids such as HC], sulfuric acid, acetic acid in the presence of solvents such as DCM, ethyl] acetate, water and the like or mixture thereof at a temperature in the range of -10 °C to 50 °C.
In another embodiment of the present invention, the compounds of general formula (I) wherein Z represents sulfur, --- represents no bond can be prepared by reacting the compound of formula (Ille)
Ro R3 "
R1 ! wherein J is halogen atom, like chlorine, bromine or iodine and R; is a lower alkyl group with thiourea followed by treatment with an acid. : :
The reaction of compound of general formula (I1le) with thiourea is carried out in the presence of alcoholic solvent such as methanol, ethanol, propanol, isobutanol, 2- methoxybutanol, etc or DMSO or sulfolane. The reaction may be conducted at a temperature in the range between 20 °C and the reflux temperature of the solvent used. Bases such as
NaOAc, KOAc, NaOMe, NaOE:t etc. can be used. 25 .
In yet another embodiment of the present invention, the compounds of the general formula (I) wherein --- represents a bond and all other symbols are as defined earlier can also be prepared by reacting a compound of formula (111) x-A~ ang wherein L is a nucleophilic leaving such as halogen atom, like chlorine, bromine or iodine;
Co methanesulfonate, trifluoromethanesulfonate, p-toluenesulfonate and the like with a compound of the formula (Ig). oo
Rr B® me Co . or ang)
Rl 4 N
The reaction of compound of general formula (IIIf) with a compound of general : formula (Ilg) to produce a compound of general formula (I) may be carried out in the presence of solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof. The reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as Ny, Ar or He. The reaction may be effected in the presence of a base such as alkalis like sodium hydroxide or potassium hydroxide; alkali metal carbonates like sodium carbonate or potassium carbonate; alkali metal hydrides such as sodium hydride; organometallic bases like n-butyl lithium; alkali metal amides like sodamide, or mixtures thereof. Multiple solvents and bases can be used. The amount of base may range from 1 to 5 equivalents, preferably 1 to 3 equivalents. The reaction temperature may be in the range of 0 °C to 120 °C, preferably at a temperature in the range of 20 °C to 100 °C. The duration of the reaction may range from 0.5 to 24 hours, preferably from 0.5 to 6 hrs.
In yet another embodiment of the present invention, the compounds of the general formula (I) wherein --- represents a bond and all other symbols are as defined earlier can also be prepared by reacting a compound of formula (I1Th)
X~A~0OH (111k) where A and X are as defined earlier with a compound of the formula (I1Ig).
Ro R3 4
RN
The reaction of compound of general formula (IITh) with a compound of general formula (IIlg) to produce a compound of general formula (I) may be carried out in the presence of solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof, The reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as Na, Ar or He. The reaction may be effected in the presence of a base such as alkalis like sodium hydroxide or potassium hydroxide; alkali metal carbonates like sodium carbonate or potassium carbonate; alkali metal hydrides such as sodium hydride; organometallic bases like n-butyl lithium; alkali metal amides like sodamide, or mixtures thereof. Multiple solvents and bases can be used. The amount of base may range from 1to 5 equivalents, preferably 1 to 3 equivalents. The reaction temperature may be in the range of 0 °Cto 120 °C, preferably at a temperature in the range of 20 °C to 100 °C. The duration of the : reaction may range from 0.5 to 24 hours, preferably from 0.5 to 6 hrs.
In another embodiment of the present invention, there is provided a process for the preparation of compounds of formula (I), wherein -— represents no bond by reducing compounds of formula (I) wherein --- represents a bond and all other symbols are as defined earlier. The reduction may be carried out in the presence of gaseous hydrogen and a catalyst such as Pd/C, R/C, Pt/C, Raney Nickel, and the like. Mixtures of catalysts may be used. The reaction may be conducted in the presence of solvents such as dioxane, acetic acid, ethyl acetate and the like. Mixtures of solvents may be used. A pressure between atmospheric pressure to 100 psi may be employed. The catalyst may be 5-10% Pd/C and the amount of catalyst used may range from 50-300% w/w. The reaction may also be carried out by . employing metal solvent reduction such as magnesium in methanol or sodium amalgam in methanol. The reaction may also be carried out with alkali metal borohydrides such as
LiBH,4, NaBH, KBH, and the like in the presence of cobalt salt such as CoCl, and ligands, preferably bidentated ligands such as 2,2'-bipyridyl, 1,10-phenanthroline, bisoximes and the like.
In yet another embodiment of the present invention, there is provided an intermediate of formula (IIIc) : R2 R3 - amy LR ao :
R1 their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, wherein
) : Y represents oxygen, sulfur or NR, wherein R represents hydrogen or alkyl; Ry, Rz, Ry and ~ R4 may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents substituted or unsubstituted aryl; X represents an alpha amino carboxylic acid or its derivatives bonded to A through its alpha ~§ side chain. | :
In yet another embodiment of the present invention, there is provided an intermediate of formula (le) : oe wo Bor oo y Pg SRG ali)
R1 ! their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, wherein
Y represents oxygen, sulfur or NR, wherein R represents hydrogen or alkyl; Ry, Ra, R3 and
Ry may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents substituted or unsubstituted aryl; X represents an alpha amino carboxylic acid or its derivatives bonded to A through its alpha side chain; J represents halogen atom and Rs represents lower alkyl group.
It has been surprisingly found that, unlike other thiazolidine-compounds (TZD molecules), compounds of the invention exhibit no adipocyte differentiation. It is also surprising that administration reduces body weight gain. Finally, compounds of the invention appear to have no affinity for PPAR-g. These three features of the compounds are different from known TZD molecules, which typically have adipocyte differentiation activity, increase weight gain, and are PPAR-g agonists. Furthermore, compounds of the invention have anti-inflammation properties. For example, the compounds inhibit TNFa, IL- 6 and IL1P.
The compounds according to the present invention may be combined with a physiologically acceptable vehicle in a pharmaceutical composition. The particularly preferred form of composition is an orally administrated capsule or solution in which the compound is delivered in water, saline, a phosphate buffer, or lyophilized powder in a form of tablets or capsules which also includes various fillers and ‘binders. The effective dosages of compound in a composition will be selected by those of ordinary skill in the art and may "be empirically determined. : | } EE
The compounds of the present invention are useful for the treatment of inflammation, . autoimmune diseases such as multiple sclerosis, IBD, obesity, neurological discases, hypertension, and diseases such as diabetes characterized by the presence of elevated blood glucose levels, that is hyperglycemic disorders such as diabetes mellitus, including both Type
I and Type II diabetes as well as other hyperglycemic related “disorders such. as hyperlipidemia, kidney related disorders, and the like. :
By “treatment,” it is meant that the compound is administered at least to reduce inflammation, hypertension, obesity, blood lipid levels, blood glucose levels or symptoms associated with autoimmune or neurological disease or disorder from which the patient is suffering. The compound is administered in an amount sufficient, for example, to reduce blood glucose level to an acceptable range, wherein an acceptable range means +- 10%, usually +/- 8% and usually +/- 5% of the normal average blood glucose level for the subject.
A variety of subjects may be treated with the compounds such as livestock, valuable Or rare animals, pets, as well as humans. The compounds may be administered to the subject using a convenient administration technique, including intravenous, intradermal, intramuscular, subcutaneous, oral administration and the like. However, the oral route of administration is particularly preferred. The dosage delivered to the host will necessarily depend upon the route by which the compound is delivered, but generally ranges from 5 to 500 mg/70 kg human body weight.
The invention is explained in detail in the examples given below which are provided by way of illustration only and therefore should not be construed to limit the scope of the invention.
Example 1
Preparation of 5-[4-(4-(2-amino-2-methoxycarbonylethyl)phenoxy)benzyl}-thiazolidin- - 2,4-dione hydrochloride salt :
. HCL NH, S_o oo . wood OL Lr
Preparation of methyl-2-[(t-butoxycarbonyl)amino}-3-[-(4-formylphenoxy) phenyl)propanoate
To a suspension of fresh sodium hydride (0.813 g, 33.9 mmol) in dry DMF (20 ml) under nitrogen atmosphere was added the solution of methyl-2-[(t-butoxycarbonyl)amino}-3-(4- hydroxyphenyljpropanoate (10 g, 33.9 mmol) in DMF (20 ml) slowly. The mixture was stirred for 15 minutes. 4-Fluorobenzaldehyde (4.20 g,-33.9 mmol) was added and the mixture was heated to 80 °C. After completion of the reaction, the solvent was removed by high vacuum and the mixture was quenched with addition of saturated aqueous ammonium chloride. The mixture was extracted with ethyl acetate (3 x50 ml). After washing with brine and dried on anhydrous sodium sulfate, the solvent was evaporated and the product was purified with flash column from eluent of hexanes: ethyl ether; 12/ 30 to 12/22 to afford the title compound as an oil (yield 11.5 g, 85.0 %). : 'H NMR (CDCls, 360 M Hz): § 9.92 (s, 1H), 7.83 (d, 2H), 7.19 (d, 2H), 7.05 (d, 2H), 7.03(d, 2H), 4.60(t, 1H), 3.72(s, 3H), 3.09(d, 2H), 1.42(s, 9H). The structure was confirmed by Mass
Spec. Calculated (M+1) 400.4; Measured 400.3.
Step (iD)
Preparation of 5-[4-(4-(2-t-butoxycarbonylamino-2-methoxycarbonylethyl) phenoxy)benzilidene]thiazolidin-2,4-dione
To a solution of methyl-2-[(t-butoxycarbonyl)amino]-3-{-(4-formylphenoxy) phenyl]propanoate obtained in step (i) above in anhydrous toluene (10 g, 25 mmol), 2,4- thiazolidinedione (3.53 g, 30 mmol) was added followed by benzoic acid (0.46 g, 3.75 mmol) and piperidine (0.28 g, 3.25 mmol). The solution was heated to reflux at 145-155 °C with continuous removal of water using Dean-Stark apparatus for 5 hr. The solution was cooled to RT and the yellow solid was precipitated to afford the title compound (yield 11.9 g, 96%, purity 96.5 % by HPLC, mp : 160-164 °C).
"HNMR (CDCl;,360 M Hz,): 7.82(s, 1H), 7.47(d, 2H); 7.05(4, 2H), 7.00(d, 2H); 6.75(d, 2H) 5.18(m, 1H), 4.54(M, 1H), 3.71(s, 3H); 3.02(m, 2H), 3.00(m, 2H). 1.42(s, 9H). The structure was confirmed by Mass Spec. Calculated (M+1) 498.5 ; Measured 498.5. | Step (iii) :
Preparation 5-[4-(4-(2-amino-2-methoxycarbonyletbyDphenoxy)benzilidene]thiazolidin- 2,4-dione
A solution of 5-[4-(4-(2-t-butoxycarbonylamino-2-methoxycarbonylethyl) phenoxy)benzilidenelthiazolidin-2,4-dione (2 g, 4.0 mmol) in DCM (100 ml) at 0 °C was bubbled with HC1 gas, After stirring for 1 hour, the yellow precipitate was filtered and 1.7 g (3.9 mmol) of HC1-Tyr (C6H4-CH=TDZ)-OMe was collected with 97.5% yield, mp : 187- 190 °C. The HPLC purity of product was 94.5%. Compound 1.
TH NMR (D20, 360 M Hz,): 7.46(s, NH, 1H); 7.24(d, 2H); 7.16(d, 2H); 6.94(d, 2H); 6.78(d, 2H); 4.80 (s, NH3, 3H); 4.40(m, Ca-H, 1H); 3.80(s, OMe). The structure was confirmed by
Mass Spec. Calculated (M+1) 501.5 ; Measured 501.5. oo
Step (iv)
Preparation of 5.[4-(4-(2-amino-2-methoxycarbonylethyl) phenoxy)benzyl]thiazolidin- 2,4-dione
To a solution of 5-[4-(4-(2-amino-2-methoxycarbonylethyl) phenoxy)benzilidene]thiazolidin-2,4-dione (0.7 g, 1.6 mmol) in methanol (20 ml) dry Pd/C (0.15 g) was added. After hydrogenating at 60 psi at 40 °C over night, the solution was filtered with Celite and evaporated under reduced pressure to yield quantitatively the title compound. This compound did not show melting in DSC but changes to black colour, in capillary and shrinks at 97-133 °C. Compound 2.
The pharmaceutically acceptable salts may be prepared by reacting the compound of formula (I) with 1 10 4 equivalents of a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium t-butoxide, calcium hydroxide, magnesium hydroxide and the like, in solvents like ether, THF, methanol, t-butanol, dioxane, isopropanol, ethanol etc.
Mixtures of solvents may be used. Organic bases like lysine, arginine, diethanolamine,
3 choline, guanidine and their derivatives etc. may also be used. Alternatively, acid addition ©. salts are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulfonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid, salicylic acid, hydroxynaphthoic acid, ascorbic acid, palmitic acid, succinic acid, benzoic acid, benzene sulfonic acid, tartaric acid and the like in solvents like ethyl acetate, ether, alcohols, acetone, THF, dioxane etc. Mixture of solvents may also be used. :
The present invention also provides a pharmaceutical composition, containing one or more of the compounds -of the general formula (I) as defined above, their tautomeric forms, their derivatives, their analogues, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates in combination with the usual pharmaceutically employed carriers, diluents and the like.
The pharmaceutical composition may be in the forms normally employed, such as tablets, capsules, powders, syrups, solutions, suspensions and the like, may contain flavourants, sweeteners etc. in suitable solid or liquid carriers or diluents, or in suitable sterile media to form injectable solutions or suspensions. Such compositions typically contain from 1 to 25%, preferably 1 to 15% by weight of active compound, the remainder of the composition being pharmaceutically acceptable carriers, diluents, excipients or solvents.
Suitable pharmaceutically acceptable carriers include solid fillers or diluents and sterile aqueous or organic solutions. The active compound will be present in such pharmaceutical compositions in the amounts sufficient to provide the desired dosage in the range as described above. Thus, for oral administration, the compounds can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, powders, syrups, solutions, suspensions and the like. The pharmaceutical compositions, may, if desired, contain additional components such as flavourants, sweeteners, excipients and the like. For parenteral administration, the compounds can be combined with sterile aqueous or organic media to form injectable solutions or suspensions. For example, solutions in sesame or peanut oil, aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble pharmaceutically-acceptable acid addition salts or alkali or alkaline earth metal salts of the compounds. The injectable solutions prepared in this manner can then be,
administered intravenously, intraperitoneally, subcutaneously, or intramuscularly, with intramuscular administration being preferred in humans.
The pharmaceutical composition of the present invention are particularly effective in . lowering blood glucose, serum insulin and triglyceride levels in animal models of types II diabetes. The pharmaceutical compositions of the present invention are also effective in the "treatment of obesity, inflammation, autoimmune diseases. Furthermore, pharmaceutical composition of the present invention are useful for the treatment of disorders associated with insulin resistance, such as polycystic ovary syndrome, as well as hyperlipidemia, coronary artery disease and peripheral vascular disease, and for the treatment of inflammation and immunological diseases, particularly those mediated by cytokines such as TNF-a, IL-1, IL-6 and cyclooxygenase such as COX-2.
Protocols for biological testing o
Compounds of the present invention have been tested for lowering inflammatory ¢ytokines level, chemically-induced inflammation, obesity and blood glucose, in different models for their biological activity. The attached figures 1-9. shows the activity profile of the representative compound.
FIGURE 1. Compounds 1 and 2 in Example 1 inhibit major pro-inflammatory cytokines in human monocyte cells
Human THP-1 monocyte cells were cultured and incubated with two compounds ‘of example 1 at different concentrations. Cells were then challenged with lipopolysaccharides (LPS) at a concentration of (1 microgram/ml) for 24 hours. Cell supematants were then analyzed for the presence of TNFa, IL1B and IL-6 cytokines by antibody directed enzyme-linked immunoassay. As shown in Figure 1, the example compounds can inhibit the production of three major pro-infalmmatory cytokines in a dose dependent manner. No significant change in cell viability was observed with incubation of cells in the presence of highest . concentration of the compound. These strongly indicate that compound of example 1 is highly effective in reducing the production of pro-inflammatory cytokines.
: FIGURE 2. Compound 2 in Example 1 can Jower Carrageenan induced inflammation in rats. | : . Spegue-Dowley rats of average weight 250g (6-7 weeks of age) were randomized in three goups, and given 50 mgkg oral dose of compound of example 1. Thirty minutes later carrageenan was administered in the sub-planter region of right hind paws. Control group © received equal volume of water without any compound. Paw volume was measured after2 and three hours. Dexamethasone at a concentration of 5 mg/kg was used as a positive control in this experiment. As shown in Figure 2, the compound of example 1 can substantially - lower the inflammation induced by carrageenan. At time 3 hours the effect of compound of example -1 was as effective as dexamethasone (a known anti-inflammatory drug that acts via different mechanism pathways).
FIGURE 3. Compounds 1 and 2 in Example 1 prevent EAE in mice (Multiple Sclerosis
Model)
Multiple sclerosis (MS) is an autoimmune disease and is regulated by cytokine levels. In order to test the effect of example 1 in MS model, experimental allergic encepahalomyalitis (EAE) was induced in SJL/J mice. EAE is an autoimmune inflammatory disease of the central nervous system (CNS). The disease shows many similarities with the human MS, and hence is used as a model to test the potential efficacy of new drugs that may have applicability in MS. EAE was induced by injecting spinal chord homogenate where animals were treated with example compounds. The severity of EAE was established by clinical scores of paralysis. As shown in Figure 3, the new compound treated group showed complete prevention of EAE. These results indicate utility of the example compounds for the treatment of MS and other neurological disorders.
FIGURE 4. Schematic representation of cytokine modulation and immune disorders.
Macrophage produces various cytokines upon stimulation by mitogens and other unknown factors. Few of theses key cytokines are known to be involved in various immunological disorders including a number of autoimmne diseases. :
FIGURE 5. Direct and indirect Linkage of TNFa in Metabolic diseases.
It has been well established that TNFa. plays a major role in inflammatory diseases and autoimmune disorders with treatments available for rheumatoid arthritis using antibody against TNFa. In addition, a number of studies in recent years have predicted the possible role of TNFa in adipose biology and metabolic disorders :such as diabetes, obesity, hyperlipidemic and vascular complications. The schematic illustration reflects how the regulation of TNFa can have impact on a number of metabolic diseases, that can provide different pathways for treating these diseases.
FIGURE 6. Compound 2 in Example 1 substantially improves hyperglycemia in. diabetic mice. | E
The hypoglycemic effect of the compound has been examined in two spontaneous animal models of diabetes (ob/ob and db/db mice). The ob/ob mice lacks leptin gene and is also considered a typical model for obesity. The db/db mice have defective leptin receptor and show hyperglycemia with significant weight gain. The compound at a dose of 5, 10 and 50 16 mg/kg body weight was given orally in these animals for a period of 15-21 days. Treatment of both ob/ob and db/db diabetic animals resulted in significant improvement of hyperglycemic conditions. Results are essentially the same for compound 1.
FIGURE 7. The Compounds 1 and 2 in Example 1 reduce body weight gain in animal . 20 model of obesity.
The leptin knock-out mice (ob/ob) are considered a suitable model for obesity besides diabetes. In order to test the efficacy of these compounds towards obesity, ob/ob mice were treated with compound for 21 days. As shown in Figure 7, single dose daily treatment of ob/ob mice with compound can result in 35% improvement in body weight gain, indicating the utility of these compounds for the treatment of obesity. This finding is opposite from that using other thiazolidines, which typically increase weight.
FIGURE 8. The Compound 2 in Example 1 can improve insulin resistance and lipid homeostasis.
The leptin knock-out ob/ob mice is also considered a good model for insulin resistance.
Treatment of these animals with the compound 2 lowered serum insulin concentration by
>70%. Similarly, a 48% decrease in triglyceride level and >50% decrease in serum cholesterol concentrations were observed in 15-day treatment study. These results indicate that the compounds have strong anti-lipidemic properties and can improve the sensitivity of insulin. _
In a separate study, surprisingly it was observed that these compounds are non-adipogenic in contrast to other known thiezolidinediones and has very weak or no affinity towards peroxisome proliferator activator receptor-gamma (PPAR-7). All of these biological findings suggest the compounds have novel properties and work by a very different mechanism of action from PPAR-y binding.
FIGURE 9. Known PPAR-g agonist rosiglitazone is an adipogenic agent, but
Compound 2 is not.
Human subcutaneous preadipocytes were cultured in 96 well plate in presence of vehicle or different doses (0.01, 0.1, 1.0, and 10 microMolar) of either rosiglitazone (BRL) or compound 2 (BLX) for 13 days. Every 72 hours media were changed with fresh compound.
As TNF inhibits adipogenesis process, it was kept as negative control of the experiment where coincubation with rosiglitazone showed a significant reduction in adipogenesis compared to rosiglitazone alone. On day 13 cells were fixed and lipid (triglycerides) accumulation was measured by staining with Oil Red O and pictures were under the microscope. To have more quantitative data, Oil Red O was extracted by adding isopropanol and measured spectrophotometrically at 540 nM (as shown in the bar graph). It can be seen that regardless of dosage, compound 2 did not cause accumulation of lipids. Rosiglitazone showed a dose dependent increase in lipid production, which could be inhibited by addition of TNFa.
Claims (52)
- : Claims: : a I A compound formula (I) : : Raz R3 RA nmr 0 : Rt oN its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, wherein ---- represents an optional double bond; ¥ - represents oxygen, sulfur or NR, wherein R represents hydrogen or alkyl; Z represents oxygen or sulfur; Rj, Rs, R3 and Rs may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents a bond or substituted or unsubstituted aryl, heterocyclyl or heteroaryl ring; X represents an alpha amino carboxylic acid or alpha amino carboxylic acid derivative bonded to A or Y through its alpha side chain.
- 2. A compound of formula (I) according to claim 1, wherein the X-A-Y-represents an amino acid selected from the group consisting of substituted or unsubstituted arginine, asparagine, cysteine, glutamine, histidine, lysine, methionine, omithine, proline, serine, threonine, tryptophan, tyrosine and their derivatives.
- 3. A compound according to claim 1 wherein A represents a substituted or unsubstituted alkyl, heterocyclyl or heteroaryl ring.
- 4. A compound according to claim 1 wherein X-A- represents an amino acid selected from the group consisting of alanine, glycine, isoleucine and leucine and their derivatives.
- 5. A compound according to claim 1 wherein A represents a bond.
- 6. A compound according to any of claims 1 through 5 wherein Z is sulfur and Y is oxygen.
- 7. A compound according to any of claims 1 through 5 wherein R; through R, are hydrogen.
- 8. A compound according to any of claims 1 through 5 wherein the --- double bond is present.
- 9, A compound according to any of claims 1 through 5 wherein the -- double bond is absent.
- 10. A compound according to claim 2 wherein X-A-Y- comprises tyrosine.
- 11. A compound according to claim 2 wherein X-A-Y comprises a tyrosine derivative.
- 12. A compound according to claim 11 wherein said derivative comprises an alkyl ester of tyrosine.
- 13. A compound according to claim 12 wherein said ester is the methyl ester.
- 5. 14. A compound according to claim 10 or 11 wherein Ry, Ry, R3 and Ry are hydrogen and Z is sulfur. :
- 15. A compound according to claim 14 wherein the --- double bond is present. oo
- 16. A compound according to claim 14 wherein the --- double bond is absent.
- 17. A compound according to claim 1, which is selected from the group consisting of: 10 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)benzilidene]thiazolidin-2,4-dione or its salts ; 5-[4-(4-(2- Amino-2-methoxycarbonylethyl)phenoxy)benzilidene]thiazolidin-2,4-dione or its salts; : [4-(4-(2-Amino-2-carboxyethyl)phenoxy)benzyl]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)benzyl]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)benzilideneloxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)benzilidene]oxazolidin-2,4-dione or its salts; 5-[4~(4-(2-Amino-2-carboxyethyl)phenoxy)benzyljoxazolidin-2,4-dione or its salts;5.]4-(4~(2-Amino-2-methoxycarbonylethyl)phenoxy)benzyl]oxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,6-difluorobenzilideneJoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,6-difluorobenzilidene] ~~ oxazolidin- 2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,6-difluorobenzyljoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,6-difluorobenzyl] oxazolidin-2,4- ~ dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,6-difluorobenzilidene]thiazolidin-2,4-dione or its salts;5.{4-(4-(2- Arnino-2-methoxycarbonylethyl)phenoxy)-2,6-difluorobenzilidene] thiazolidin- 2,4-dione or its salts; oo 5-[4-(4-(2- Amino-2-carboxyethyl)phenoxy)-2,6-difluorobenzyl]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,6-difluorobenzyl] thiazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,3-diflucrobenzilidene]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,3-diflucrobenzilidene] thiazolidin- : 2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,3-diflucrobenzyljthiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,3-difluorobenzyl] thiazolidin-2,4- "15 dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,3-difluorobenzilidene]oxazolidin-2,4-dione or its salts; 5-{4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,3-difluorobenzilidene] oxazolidin- 2,4-dione or its salts;5.[4-(4-(2- Amino-2-carboxyethyl)phenoxy)-2,3-diflucrobenzyljoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,3-difluorobenzyl] oxazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-methylbenzilidene]oxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-methylbenzilidene] oxazolidin-2,4- dione or its sats; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-methylbenzyljoxazolidin-2,4-dione or its salts;oo 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-methylbenzyljoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-methylbenzilidene]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-methylbenzilidene] thiazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-methylbenzyl]thiazolidin-2,4-dione or its salts;5.[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-methylbenzy!]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2- Amino-2-carboxyethyl)phenoxy)-3-nitrobenzilidene]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-nitrobenzilidene] thiazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3 -nitrobenzyl]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-nitrobenzyl]thiazolidin-2,4-dione or. its salts; : 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-nitrobenzilidene]oxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-nitrobenzilidene] oxazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-nitrobenzylJoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-nitrobenzyl]Joxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-aminobenzilidene]thiazolidin-2,4-dione or its salts;5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-aminobenzilidene] thiazolidin-2.4- dione or its salts;5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-aminobenzyl]thiazolidin-2,4-dione or its salts;5. [4-(4-(2- Amino-2-methoxycarbonylethyl)phenoxy)-3-aminobenzyl thiazolidin-2,4-dione or its salts; : 5-[4-(4~(2- Amino-2-carboxyethyl)phenoxy)-3-aminobenzilideneJoxazolidin-2,4-dione or its salts; | | Co 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-aminobenzilidene] oxazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-aminobenzylJoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)- 3-aminobenzylJoxazolidin-2,4-dione or its salts; 5-[4-(4-(2- Amino-2-carboxyethyl)phenoxy)-2-fluorobenzilidene]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2-fluorobenzilidene] thiazolidin-2,4- dione or its salts; : 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2-fluocrobenzyl]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenozxy)-2-fluorobenzyi]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2-fluorobenzilidene]Joxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2-fluorobenzilidene] ~~ oxazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2-fluorobenzyl]oxazolidin-2,4-dione or its salts ; 5-[4-(4-(2- Amino-2-methoxycarbonylethyl)phenoxy)-2-flucrobenzyljoxazolidin-2,4-dione or its salts;5.[4~(4-(2- Amino-2-carboxyethyl)phenoxy)-3-fluorobenzilidene]thiazolidin-2,4-dione or its salts; h 5-[4-(4-(2- Amino-2-methoxycarbonylethyl)phenoxy)-3-fluorobenzilidene] thiazolidin-2,4- dione or its salts; 5 -[4-(4-(2-Amino-2-carboxyethy!)phenoxy)-3-flucrobenzyl]thiazolidin-2,4-dione or its salts; 5-[4-(4~(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-flucrobenzyl]thiazolidin-2,4-dione or its salts; | :5.[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-fluorobenzilidene]oxazolidin-2,4-dione or. its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-fluorobenzilidene] oxazolidin-2,4- dione or its salts; - 5-[4-(4-(2- Amino-2-carboxyethyl)phenoxy)-3-flucrobenzyl]oxazolidin-2,4-dione or its salts ; © 5-[4-(4-(2- Amino-2-methoxycarbonylethyl)phenoxy)-3-fluorobenzyljoxazolidin-2,4-dione 15° or its salts; | : 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2-trifluoromethylbenzilidene] thiazolidin-2,4- dione or its salts;5.[4-(4~(2-Amino-2-methoxycarbonylethyl)phenoxy)-2-trifluoromethylbenzilidene] thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2-trifluoromethylbenzyl]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2-trifluoromethylbenzyl] thiazolidin- 2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2-trifluoromethylbenzilidene] oxazolidin-2,4- dione or its salts; ‘5.[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2-triflucromethylbenzilidene] oxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2-trifluoromethylbenzyl]oxazolidin-2,4-dione or its salts;: 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2-trifluoromethylbenzyl] oxazolidin- © 2,A-dione or its salts; : oo : 5-[4-(4-(2-Arhino-2-carboxyethyl)phenoxy)-3-triffuoromethylbenzilidene] - thiazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-trifluoromethylbenzilidene) thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-trifluoromethylbenzyl]thiazolidin-2,4-dione or its salts; | Co5-[4-(4-(2- Amino-2-methoxycarbonylethyl)phenoxy)-3-triflucromethylbenzyl] thiazolidin- 2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-trifluoromethylbenzilidene] ~~ oxazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-trifluoromethylbenzilidene]oxazolidin-2,4-dione or its salts; ) 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-trifluoromethylbenzyl]oxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-trifluoromethylbenzyl] oxazolidin- 2,4-dione or its salts;5-[4-(4~(2-Amino-2-carboxyethyl)-2,6-difluorophenoxy)benzilidene]oxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2,6-difluorophenoxy)benzilidene] ~~ oxazolidin- 2,4-dione or its salts5-[4-(4-(2-Amino-2-carboxyethyl)-2,6-difluorophenoxy)benzyl]oxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2,6-difluorophenoxy)benzyl] oxazolidin-2,4- dione or its salts; 5-{4-(4-(2-Amino-2-carboxyethyl)-2,6-difluorophenoxy)benzilidene]thiazolidin-2,4-dione or its salts;5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2,6-difluorophenoxy)benzilidene] thiazolidin- . 2,4-dione or its salts;5.[4-(4-(2-Amino-2-carboxyethyl)-2,6-diflucrophenoxy)benzyl thiazolidin-2,4-dione or its salts; :5.[4-(4-(2- Amino-2-methorycarbonylethyl)-2,6-difluorophenoxy)benzyl] thiazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-2,3-difluorophenoxy)benzilidene]thiazolidin-2,4-dione or its salts - ’5.[4-(4-(2-Amino-2-methoxycarbonylethyl)-2,3-difluorophenoxy)benzilidene] thiazolidin- 2,4-dione or its salts;5.[4-(4-(2-Amino-2-carboxyethyl)-2,3-difluorophenoxy)benzyl]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2- Amino-2-methoxycarbonylethyl)-2,3-difluorophenoxy)benzyl] thiazolidin-2,4- dione or its salts; :5. [4-(4-(2-Amino-2-carboxyethyl)-2,3-difluorophenoxy)benzilideneJoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2,3-difluorophenoxy)benzilidene}-oxazolidin- 2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-2,3-difluorophenoxy)benzyljoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2,3-difluorophenoxy)benzyl} | oxazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-3-methylphenoxy)benzilideneJoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-methylphenoxy)benzilidene] oxazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-3-methylphenoxy)benzyljoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-methylphenoxy)benzyljoxazolidin-2,4-dione or its salts;oC 5.[4-(4-(2-Amino-2-carboxyethyl)-3-methylphenoxy)benzilidene]thiazolidin-2,4-dione or its salts;5.[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-methylphenoxy)benzilidene] thiazolidin-2,4- dione or its salts; ’ 5-[4-(4-(2-Amino-2-carboxyethyl)-3-methylphenoxy)benzylthiazolidin-2,4-dione or its salts; :5.[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-methylphenoxy)benzyl]thiazolidin-2,4-dione - or its salts; :| 5.[4-(4-(2-Amino-2-carboxyethyl)-3-nitrophenoxy)benzilidene]thiazolidin-2,4-dione or its salts;5.[4-(4-(2-Amino-2-methoxycarbonylethy!)-3-nitrophenoxy)benzilidene] thiazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-3-nitrophenoxy)benzyl]thiazolidin-2,4-dione or its salts;5. [4-(4-(2- Amino-2-methoxycarbonylethy)-3-nitrophenoxy)benzylthiazolidin-2,4-dione or its salts;5.[4-(4-(2-Amino-2-carboxyethyl)-3-nitrophenoxy)benzilidene]oxazolidin-2,4-dione or its salts; . , . 5-[4-(4~(2- Amino-2-methoxycarbonylethyl)-3-nitrophenoxy)benzilidene] oxazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-3-nitrophenoxy)benzyljoxazolidin-2,4-dione or its salts;5.[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-nitrophenoxy)benzyl]oxazolidin-2,4-dione or its salts; . 5-[4-(4-(2-Amino-2-carboxyethyl)-3-aminophenoxy)benzilidene]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-aminophenoxy)benzilidene] thiazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-3-aminophenoxy)benzyljthiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-aminophenoxy)benzyl]thiazolidin-2,4-dione or its salts;5-[4-(4-(2-Amino-2-carboxyethyl)-3-aminophenoxy)benzilidene]oxazolidin-2,4-dione or its salts; B 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-aminophenoxy)benzilidene] oxazolidin-2,4- dione or its salts; : 5-[4-(4-(2-Amino-2-carboxyethyl)-3-aminophenoxy)benzyl]oxazolidin-2,4-dione or its salts;. 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-aminophenoxy)benzyljoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-2-fluorophenoxy)benzilidene]thiazolidin-2,4-dione or its salts; : 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2-fluorophenoxy)benzilidene] thiazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-2-fluorophenoxy)benzy!]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2-fluorophenoxy)benzyljthiazolidin-2,4-dione or its salts; ) ’ : 5-[4-(4-(2-Amino-2-carboxyethyl)-2-fluorophenoxy)benzilideneloxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2-fluorophenoxy)benzilidene] oxazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-2-fluorophenoxy)benzyljoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2-fluorophenoxy)benzyljoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethy})-3-fluorophenoxy)benzilidene]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-fluorophenoxy)benzilidene] thiazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-3-fluorophenoxy)benzyl]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-fluorophenoxy)benzyljthiazolidin-2,4-dione or its salts; 54 oo5-[4-(4-(2-Amino-2-carboxyethyl)-3-flucrophenoxy)benzilideneJoxazolidin-2,4-dione or its salts; : 5-[4-(4-(2- Amino-2-methoxycarbonylethyl)-3-flucrophenoxy)benzilidene] oxazolidin-2,4- dione or its salts; :5.[4-(4-(2-Amino-2-carboxyethyl)-3-fluorophenoxy)benzyljoxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-fluorophenoxy)benzyljoxazolidin-2,4-dione or its salts; 5-[4-(4-(2: Amino-2-carboxyethyl)-2-trifluoromethylphenoxy)benzilidene] thiazolidin-2,4- dione or its salts; : 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2-trifluoromethylphenoxy) . benzilidene] thiazolidin-2,4-dione or its salts; 5-[4-(4:(2-Amino-2-carboxyethyl)-2-trifluoromethylphenoxy)benzylJthiazolidin-2,4-dione or its salts; 16 5.[4-(4-(2- Amino-2-methoxycarbonylethyl)-2-triflucromethylphenoxy)benzyi] thiazolidin- 2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-2-triflucromethylphenoxy)benzilidene] ~~ oxazolidin-2,4- dione or ts salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2-trifluoromethylphenoxy) benzilidene] oxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-2-trifluoromethylphenoxy)benzyl]oxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2-trifluoromethylphenoxy)benzyl] oxazolidin- 2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-3-trifluoromethylphenoxy)benzilidene] thiazolidin-2,4- dione or its salts; 5-[4-(4-(2-Amino-2-methoxycarbony! ethyl)-3-trifluoromethylphenoxy) benzilidene] thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-3-trifluoromethylphenoxy)benzyl]thiazolidin-2,4-dione or its salts;. 5-[4-(4-(2- Amino-2-methoxycarbonylethyl)-3-trifluoromethylphenoxy)benzyl] thiazolidin- . 2,4-dione or its salts; : a 5-[4~(4-(2-Amino-2-carboxyethyl)-3-trifluoromethylphenoxy)benzilidene] oxazolidin-2,4- dione or its salts; : | : 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-trifluoromethylphenoxy) benzilidene] oxazolidin-2,4-dione or its salts; 5-[4-(4-(2-Amino-2-carboxyethyl)-3-triflucromethylphenoxy)benzyljoxazolidin-2,4-dione or its salts;5.[4-(4-(2- Amino-2-methoxycarbonylethyl)-3-trifluoromethylphenoxy)benzyl] oxazolidin- 2,4-dione or its salts;5.[4-(4-(2-t-butoxycarbonylamino-2-methoxycarbonylethyl)phenoxy) benzilidene] thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-t-butoxycarbonylamino-2-methoxycarbonylethyl)phenoxy) benzyllthiazolidin-2,4- dione or its salts; 5-[4-(4-(2-t-butoxycarbonylamino-2-methoxycarbonylethyl)phenoxy) benzilidene) oxazolidin-2,4-dione or its salts;5.[4-(4-(2-1-butoxycarbonylamino-2-methoxycarbonylethyl)phenoxy) benzylJoxazolidin-2,4- dione or its salts. 5-[4-(4-(2-t-butoxycarbonylamino-2-carboxyethyl)phenoxy) benzilidene]thiazolidin-2,4- dione or its salts; 5-[4-(4-(2-t-butoxycarbonylamino-2-carboxyethyl)phenoxy)benzyl]thiazolidin-2,4-dione or its salts; 5-[4-(4-(2-t-butoxycarbonylamino-2-carboxyethyl)phenoxy) benzilidene]oxazolidin-2,4- dione or its salts and : 5-[4-(4-(2-t-butoxycarbonylamino-2-carboxyethyl)phenoxy)benzylJoxazolidin-2,4-dione or its salts.
- 18. A process for the preparation of an amino acid phenyl ether of formula (I)Co RY RS of : | mn Viana 0) : rR JN oo its derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, wherein --—- represents a bond; Y represents oxygen, sulfur or NR, wherein R represents hydrogen or alkyl; Z represents oxygen or sulfur; R;, Ra, R; and Rs may be same or different and - independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents a bond or substituted or unsubstituted aryl, heterocyclyl or heteroaryl ring; X represents an alpha amino carboxylic acid or its derivatives bonded to A or Y through its alpha side chain, which comprises i). reacting the compound of formula (IIla) X;A~YH am) which represents a protected amino acid-and all other symbols are as defined above with the ~~ compound of formula (IIIb) R2 R3 peo qaub) R1 5 wherein L represents a nucleophilic aromatic substitution leaving group, R;, R; and R; are as defined above to produce a compound of formula (Ilic) R2 R3 xv) CRO aug R1 ji). reacting the compound of the formula (llc) with 2,4-thiazolidinedione or 2,4- oxazolidinedione to yield a compound of formula (II1d) and R2 R4 R1 o H : iii) deprotecting the amino acid group of formula (I11d) to yield compound of formula (I).
- 19. A process for the preparation of amino acid phenyl ethers of formula (I)re Tra z : ls Vis (1 Ri JN _ their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, wherein - --- represents no bond; Y represents oxygen, sulfur or NR, wherein R represents hydrogen or alkyl; Z represents sulfur; Ry, Ra, Rs and Ry may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents a bond or substituted or unsubstituted aryl, heterocyclyl or heteroaryl ring; X' represents an alpha amino carboxylic acid or its derivatives bonded to A or Y through its alpha side chain, by reacting the compound of formula (Ille) R2 3 4 mn COOR (lle) RIC a wherein J is halogen atom and R is a lower alkyl group with thiourea followed by treatment with an acid.
- 20. A process for the preparation of an amino acid phenyl ether of formula (I) R2 RR 4 ye 0) : Ri N its derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, wherein -— represents a bond; Y represents oxygen, sulfur or NR, wherein R represents hydrogen or alkyl; Z represents oxygen or sulfur; Rj, Rz, R3 and Rs may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents a bond or substituted or unsubstituted aryl, heterocyclyl or heteroaryl ring; X represents an alpha amino carboxylic acid or its derivatives bonded to A through its alpha side chain, by reacting a compound of formula (I11f) x—A~L (nf) wherein L is a nucleophilic leaving group with a compound of the formula (ITIg).
- o~ ‘ . . Attorney’s Docket No.: BEXIPOOLWO R2 3 R4 Rt oN
- 22. A process for the preparation of compound of formula (I) R2 R3 R4 2 rr Ly Did 0) Rt H wherein “--- represents no bond by reducing compounds of formula (I) wherein “---* represents a bond and all other symbols are as defined in claim 1.
- 23. A pharmaceutical composition, which comprises a pharmaceutically effective amount of an amino acid phenyl ether of formula (I) R2 R35 Ra Zz err =o 0) Ro HN as defined in claim 1 and a pharmaceutically acceptable carrier, diluent, excipient or solvate.
- 24. Use of a compound of formula (I) as defined in claim 1 for the manufacture of a medicament for reducing glucose in plasma.
- 25. Use of a compound of formula (I) as defined in claim 1 for the manufacture of a medicament for reducing free fatty acids in plasma.
- 26. Use of a compound of formula (I) as defined in claim | for the manufacture of a medicament for reducing cholesterol in plasma.
- 27. Use of a compound of formula (I) as defined in claim 1 for the manufacture of a medicament for reducing triglyceride levels in plasma.
- 28. Use of a compound of formula (I) as defined in claim 1 for the manufacture of a medicament for treating obesity.
- 29. Use of a compound of formula (I) as defined in claim 1 for the manufacture of a medicament for treating autoimmune diseases.
- 30. Use of a compound of formula (I) as defined in claim 1 for the manufacture of a medicament for treating inflammation.
- 31. Use of a compound of formula (I) as defined in claim 1 for the manufacture of a medicament for treating immunological disease. AMENDED SHEET a .. . Attomey's Docket No.: BEX1PO01.WO
- 32. A use according to claim 29, whercin the autoimmune discase is multiple sclerosis.
- 33. A use according to claim 29, wherein the autoimmune disease is rheumatoid arthritis.
- 34. A use according to claim 30, wherein the inflammation is mediated by cyclooxygenase.
- 35. A use according to claim 31, wherein the immunological diseases is mediated by cytokines.
- 36. Use of a compound of formula (1) as defined in claim | for the manufacture of a medicament for treating a disorder associated with insulin resistance.
- 37. An intermediate of formula (Illc) R2 R3 ‘ ay Re a) R1 its derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, wherein Y represents oxygen, sulfur or NR, wherein R represents hydrogen or alkyl; Rj, Rz, Rs and Rs; may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents substituted or unsubstituted aryl; X represents an alpha amino carboxylic acid or its derivatives bonded to A through its alpha amino side chain.
- 38. An intermediate of formula (Illc) R2 T° Ra COOR, gy (Iie) R1 its derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, wherein Y represents oxygen, sulfur or NR, wherein R represents hydrogen or alkyl; R;, R,, R; and R; may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents substituted or unsubstituted aryl; X represents an alpha amino carboxylic acid or its derivatives bonded to A through its alpha amino side chain; J represents halogen atom and Rs represents lower alkyl group. oo AMENDED SHEET‘ : Attorney's Docket No. BEX1POO1.WO
- 39. The compound as claimed in claim 1, wherein said pharmaceutically acceptable salt is selected from hydrochloride, hydrobromide, sodium, potassium or magnesium salt.
- 40. A compound of formula (I) as claimed in any one of claims 1 to 16 and 39, specifically as hereinbefore described or exemplified and not claimed in claim 17.
- 41. A compound of formula (I) including any new and inventive integer or combination of integers, substantially as herein described.
- 42. A process according to the invention for the preparation of an amino acid phenyl ether of formula (I), substantially as hereinbefore described or exemplified.
- 43. A process for the preparation of an amino acid phenyl ether of formula (I) including any new and inventive integer or combination of integers, substantially as herein described.
- 44. A pharmaceutical composition as claimed in claim 23, substantially as hereinbefore described or exemplified.
- 45. A pharmaceutical composition including any new and inventive integer or combination of integers, substantially as herein described.
- 46. Use of a compound of formula (I) as claimed in any one of claims 24 to 36, substantially as hereinbefore described or exemplified.
- 47. Use of a compound of formula (I) including any new and inventive integer or combination of integers, substantially as herein described.
- 43. An intermediate of formula (llc) as claimed in claim 37 or 38, substantially as hereinbefore described or exemplified.
- 49. An intermediate of formula (IIIc) including any new and inventive integer or combination of integers, substantially as herein described.
- 50. A compound of formula (I) or a composition comprising thereof as claimed in any one of claims 1 to 17, 23, 39 to 41 and 44 to 45 whenever supplied with instructions for the use thereof in reducing glucose, free fatty acids, cholesterol or triglyceride levels in plasma and/or in treating obesity, autoimmune diseases, inflammation, immunological diseases or a disorder associated with insulin resistence.
- 51. A compound of the formula (I) or a composition comprising thereof in claim 50 when the instructions are in printed or written form.
- 52. A compound of formula (I) or a composition comprising thereof in claim 51 supplied in a package or container having the said instructions provided therein or thereon. 0 AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44077203P | 2003-01-17 | 2003-01-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200506527B true ZA200506527B (en) | 2007-02-28 |
Family
ID=36703963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200506527A ZA200506527B (en) | 2003-01-17 | 2005-08-16 | Amino acid phenoxy ethers |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN1758907A (en) |
ZA (1) | ZA200506527B (en) |
-
2004
- 2004-01-13 CN CN 200480006737 patent/CN1758907A/en active Pending
-
2005
- 2005-08-16 ZA ZA200506527A patent/ZA200506527B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1758907A (en) | 2006-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5134974B2 (en) | 5- [4- (4- (2- (Amino-2-methoxycarbonylethyl) phenoxy) benzylidene] thiazolidine-2,4-dione derivatives and related compounds for reducing plasma glucose, cholesterol and triglyceride levels | |
US7521466B2 (en) | Dipeptide phenyl ethers | |
EP1583529B1 (en) | Amino acid phenoxy ethers, their preparation and uses | |
KR20080081099A (en) | Substituted thiazolidinedione derivatives | |
AU4948700A (en) | Hydrochloride of fused-heterocycle compound | |
ZA200506527B (en) | Amino acid phenoxy ethers | |
US20080319031A1 (en) | Novel Tyrosine Derivatives | |
EP1036075B1 (en) | Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypolipidemia and antihypertensive properties | |
JP2008526904A (en) | Hydroxyphenol derivatives, methods for their preparation, pharmaceutical compositions containing them, and therapeutic uses thereof | |
JP2008535904A (en) | New heterocyclic derivatives | |
EP0894089A1 (en) | Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them | |
JPH0440356B2 (en) | ||
JPH10182461A (en) | Visceral fat reducing agent |